<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma - Bleeker, G - 2015 | Cochrane Library</title> <meta content="123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma - Bleeker, G - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009263.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma - Bleeker, G - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009263.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009263.pub2" name="dc.identifier" scheme="DOI"/> <meta content="123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma" name="citation_title"/> <meta content="Gitta Bleeker" name="citation_author"/> <meta content="Northwest Clinics" name="citation_author_institution"/> <meta content="Godelieve AM Tytgat" name="citation_author"/> <meta content="Princess Máxima Center for Pediatric Oncology" name="citation_author_institution"/> <meta content="G.A.M.Tytgat@prinsesmaximacentrum.nl" name="citation_author_email"/> <meta content="Judit A Adam" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Huib N Caron&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="F. Hoffmann‐La Roche AG" name="citation_author_institution"/> <meta content="Leontien CM Kremer" name="citation_author"/> <meta content="Princess Máxima Center for Pediatric Oncology" name="citation_author_institution"/> <meta content="Lotty Hooft" name="citation_author"/> <meta content="Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University" name="citation_author_institution"/> <meta content="Elvira C van Dalen" name="citation_author"/> <meta content="Princess Máxima Center for Pediatric Oncology" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD009263.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/09/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009263.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009263.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009263.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*3‐Iodobenzylguanidine; *Positron‐Emission Tomography; *Tomography, Emission‐Computed, Single‐Photon; Neuroblastoma [*diagnostic imaging, pathology, secondary]; Sensitivity and Specificity" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009263.pub2&amp;doi=10.1002/14651858.CD009263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="urvLIhM4";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009263\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009263\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","fa","fr"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD009263.pub2",title:"123I\\u2010MIBG scintigraphy and 18F\\u2010FDG\\u2010PET imaging for diagnosing neuroblastoma",firstPublishedDate:"Sep 29, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Childhood Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009263.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009263.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009263.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009263.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009263.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009263.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009263.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009263.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009263.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009263.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3666 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009263.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-sec1-0006"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/appendices#CD009263-sec1-0012"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information#CD009263-cr-0002">Gitta Bleeker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information#CD009263-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Godelieve AM Tytgat</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information#CD009263-cr-0004">Judit A Adam</a></li> <li class="author custom-tooltip" title="The author was not employed by F. Hoffmann‐La Roche AG until after the work on the review was complete, and will not participate in any updates"><a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information#CD009263-cr-0005">Huib N Caron</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information#CD009263-cr-0006">Leontien CM Kremer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information#CD009263-cr-0007">Lotty Hooft</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information#CD009263-cr-0008">Elvira C van Dalen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information/en#CD009263-sec1-0014">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 September 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009263.pub2">https://doi.org/10.1002/14651858.CD009263.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009263-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009263-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009263-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009263-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009263-abs-0003">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009263-abs-0001" lang="en"> <section id="CD009263-abs1-0001"> <h3 class="title" id="CD009263-abs1-0001">Background</h3> <p>Neuroblastoma is an embryonic tumour of childhood that originates in the neural crest. It is the second most common extracranial malignant solid tumour of childhood. </p> <p>Neuroblastoma cells have the unique capacity to accumulate Iodine‐123‐metaiodobenzylguanidine (¹²³I‐MIBG), which can be used for imaging the tumour. Moreover, ¹²³I‐MIBG scintigraphy is not only important for the diagnosis of neuroblastoma, but also for staging and localization of skeletal lesions. If these are present, MIBG follow‐up scans are used to assess the patient's response to therapy. However, the sensitivity and specificity of ¹²³I‐MIBG scintigraphy to detect neuroblastoma varies according to the literature. </p> <p>Prognosis, treatment and response to therapy of patients with neuroblastoma are currently based on extension scoring of ¹²³I‐MIBG scans. Due to its clinical use and importance, it is necessary to determine the exact diagnostic accuracy of ¹²³I‐MIBG scintigraphy. In case the tumour is not MIBG avid, fluorine‐18‐fluorodeoxy‐glucose (<sup>18</sup>F‐FDG) positron emission tomography (PET) is often used and the diagnostic accuracy of this test should also be assessed. </p> </section> <section id="CD009263-abs1-0002"> <h3 class="title" id="CD009263-abs1-0002">Objectives</h3> <p>Primary objectives:</p> <p>1.1 To determine the diagnostic accuracy of ¹²³I‐MIBG (single photon emission computed tomography (SPECT), with or without computed tomography (CT)) scintigraphy for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. </p> <p>1.2 To determine the diagnostic accuracy of negative ¹²³I‐MIBG scintigraphy in combination with <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old, i.e. an add‐on test. </p> <p>Secondary objectives:</p> <p>2.1 To determine the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. </p> <p>2.2 To compare the diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) and <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. This was performed within and between included studies. ¹²³I‐MIBG (SPECT‐CT) scintigraphy was the comparator test in this case. </p> </section> <section id="CD009263-abs1-0003"> <h3 class="title" id="CD009263-abs1-0003">Search methods</h3> <p>We searched the databases of MEDLINE/PubMed (1945 to 11 September 2012) and EMBASE/Ovid (1980 to 11 September 2012) for potentially relevant articles. Also we checked the reference lists of relevant articles and review articles, scanned conference proceedings and searched for unpublished studies by contacting researchers involved in this area. </p> </section> <section id="CD009263-abs1-0004"> <h3 class="title" id="CD009263-abs1-0004">Selection criteria</h3> <p>We included studies of a cross‐sectional design or cases series of proven neuroblastoma, either retrospective or prospective, if they compared the results of ¹²³I‐MIBG (SPECT‐CT) scintigraphy or <sup>18</sup>F‐FDG‐PET(‐CT) imaging, or both, with the reference standards or with each other. Studies had to be primary diagnostic and report on children aged between 0 to 18 years old with a neuroblastoma of any stage at first diagnosis or at recurrence. </p> </section> <section id="CD009263-abs1-0005"> <h3 class="title" id="CD009263-abs1-0005">Data collection and analysis</h3> <p>One review author performed the initial screening of identified references. Two review authors independently performed the study selection, extracted data and assessed the methodological quality. </p> <p>We used data from two‐by‐two tables, describing at least the number of patients with a true positive test and the number of patients with a false negative test, to calculate the sensitivity, and if possible, the specificity for each included study. </p> <p>If possible, we generated forest plots showing estimates of sensitivity and specificity together with 95% confidence intervals. </p> </section> <section id="CD009263-abs1-0006"> <h3 class="title" id="CD009263-abs1-0006">Main results</h3> <p>Eleven studies met the inclusion criteria. Ten studies reported data on patient level: the scan was positive or negative. One study reported on all single lesions (lesion level). The sensitivity of ¹²³I‐MIBG (SPECT‐CT) scintigraphy (objective 1.1), determined in 608 of 621 eligible patients included in the 11 studies, varied from 67% to 100%. One study, that reported on a lesion level, provided data to calculate the specificity: 68% in 115 lesions in 22 patients. The sensitivity of ¹²³I‐MIBG scintigraphy for detecting metastases separately from the primary tumour in patients with all neuroblastoma stages ranged from 79% to 100% in three studies and the specificity ranged from 33% to 89% for two of these studies. </p> <p>One study reported on the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging (add‐on test) in patients with negative ¹²³I‐MIBG scintigraphy (objective 1.2). Two of the 24 eligible patients with proven neuroblastoma had a negative ¹²³I‐MIBG scan and a positive <sup>18</sup>F‐FDG‐PET(‐CT) scan. </p> <p>The sensitivity of <sup>18</sup>F‐FDG‐PET(‐CT) imaging as a single diagnostic test (objective 2.1) and compared to ¹²³I‐MIBG (SPECT‐CT) (objective 2.2) was only reported in one study. The sensitivity of <sup>18</sup>F‐FDG‐PET(‐CT) imaging was 100% versus 92% of ¹²³I‐MIBG (SPECT‐CT) scintigraphy. We could not calculate the specificity for both modalities. </p> </section> <section id="CD009263-abs1-0007"> <h3 class="title" id="CD009263-abs1-0007">Authors' conclusions</h3> <p>The reported sensitivities of ¹²³‐I MIBG scintigraphy for the detection of neuroblastoma and its metastases ranged from 67 to 100% in patients with histologically proven neuroblastoma. </p> <p>Only one study in this review reported on false positive findings. It is important to keep in mind that false positive findings can occur. For example, physiological uptake should be ruled out, by using SPECT‐CT scans, although more research is needed before definitive conclusions can be made. </p> <p>As described both in the literature and in this review, in about 10% of the patients with histologically proven neuroblastoma the tumour does not accumulate ¹²³I‐MIBG (false negative results). For these patients, it is advisable to perform an additional test for staging and assess response to therapy. Additional tests might for example be <sup>18</sup>F‐FDG‐PET(‐CT), but to be certain of its clinical value, more evidence is needed. </p> <p>The diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging in case of a negative ¹²³I‐MIBG scintigraphy could not be calculated, because only very limited data were available. Also the detection of the diagnostic accuracy of index test <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma tumour and its metastases, and to compare this to comparator test ¹²³I‐MIBG (SPECT‐CT) scintigraphy, could not be calculated because of the limited available data at time of this search. </p> <p>At the start of this project, we did not expect to find only very limited data on specificity. We now consider it would have been more appropriate to use the term "the sensitivity to assess the presence of neuroblastoma" instead of "diagnostic accuracy" for the objectives. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009263-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009263-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009263-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009263-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009263-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009263-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009263-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009263-abs-0005" lang="en"> <h3>¹²³I‐MIBG‐ and 18F‐FDG‐PET‐imaging, two nuclear imaging methods for diagnosing neuroblastoma tumours </h3> <p><b>Background and rationale</b> </p> <p>Neuroblastoma is a childhood tumour that can be visualized by a specific nuclear imaging compound, called metaiodobenzylguanidine (¹²³I ‐MIBG). ¹²³I‐MIBG‐imaging is not only important for the diagnosis of neuroblastoma, but also for localization of metastases (spread of the disease to other organs). Sometimes, the neuroblastoma does not take up ¹²³I‐MIBG and as a result the neuroblastoma is not visible on the scan. In that case, another type of nuclear imaging might be useful to visualize the neuroblastoma: fluoro‐deoxy‐glucose – positron emission tomography (<sup>18</sup>F‐FDG‐PET)‐imaging. </p> <p>In the literature the ability to discriminate between neuroblastoma and non‐neuroblastoma lesions for these two types of nuclear imaging methods vary. </p> <p>Prognosis, treatment and response to therapy of patients with neuroblastoma are currently based on scoring the amount of metastases per body segment visible on ¹²³I‐MIBG scans. Therefore, it is important to determine the exact ability to discriminate between neuroblastoma and non‐neuroblastoma on ¹²³I‐MIBG‐imaging and <sup>18</sup>F‐FDG‐PET‐imaging. We reviewed the evidence about the accuracy of ¹²³I‐MIBG‐imaging and <sup>18</sup>F‐FDG‐PET‐imaging for the detection of a neuroblastoma in children suspected of this disease. </p> <p><b>Study characteristics</b> </p> <p>We searched scientific databases for clinical studies comparing ¹²³I‐MIBG or <sup>18</sup>F‐FDG‐PET imaging, or both, with microscopic examination of tissue suspected of neuroblastoma (histopathology). The evidence is current up to 11 September 2012. </p> <p>We identified 11 eligible studies including 621 children that fulfilled our inclusion criteria: children &lt; 18 years old with a neuroblastoma and ¹²³I‐MIBG or <sup>18</sup>F‐FDG‐PET imaging or both. </p> <p>All studies included proven neuroblastoma.</p> <p><b>Quality of the evidence</b> </p> <p>All 11 included studies had methodological limitations. Only one included study provided data on specificity (the ability of a test to correctly classify an individual as 'disease‐free') and therefore we could not perform all of the planned analyses. </p> <p><b>Key results</b> </p> <p>When compared to histopathological results the sensitivity (the ability of a test to correctly classify an individual person as 'diseased') of ¹²³I‐MIBG imaging varied from 67% to 100% in patients with histologically proven neuroblastoma. This means that in 100 children with proven neuroblastoma ¹²³I‐MIBG imaging will correctly identify 67 to 100 of the neuroblastoma cases. Only one study, that reported on a lesion level, provided data to calculate the specificity (the ability of a test to correctly classify an individual as 'disease‐free'): 68% in 115 lesions. This means that of 100 disease‐free lesions in patients with proven neuroblastoma ¹²³I‐MIBG imaging will correctly identify 68 lesions. So, in about 10% of the cases the neuroblastoma is not visible on ¹²³I‐MIBG imaging (false negative results). For these cases, it is advisable to perform an additional test like <sup>18</sup>F‐FDG‐PET imaging, but to be certain of its clinical value, more evidence is needed. </p> <p>Only one included study reported on false positive findings. This means that ¹²³I‐MIBG imaging and <sup>18</sup>F‐FDG‐PET imaging incorrectly identified neuroblastoma lesions in patients which might result in wrongly classifying a patient with metastatic disease. It is important to keep in mind that false positive findings can occur, although more research is needed before definitive conclusions can be made. </p> <p>We could not determine the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET imaging, in case the neuroblastoma was incorrectly not identified with ¹²³I‐MIBG, due to limited data. Also, we could not calculate the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET imaging for detecting a neuroblastoma and compare this to ¹²³I‐MIBG imaging because of the limited available data. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009263-sec1-0007" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009263-sec1-0007"></div> <h3 class="title" id="CD009263-sec1-0008">Implications for practice</h3> <section id="CD009263-sec1-0008"> <p>In this Cochrane DTA review, we included 11 studies and found a sensitivity of 67 to 100%. Although only one included study reported on false positive findings, it is important to keep in mind that false positive findings occur. Most reported false positive findings in this one study seemed to be physiological uptake. However, this implies that ¹²³I‐MIBG scans may not be evaluated as easily as is generally thought and that it is important to rule out physiological uptake, e.g. by using SPECT‐CT scans. However, further research is needed before definitive conclusions can be made. </p> <p>As described both in the literature and in this review, in about 10% of patients with histologically proven neuroblastoma the tumour does not accumulate ¹²³I‐MIBG (false negative results). For these patients, it is advisable to perform an additional test for staging the neuroblastoma. Additional tests might for example be <sup>18</sup>F‐FDG‐PET(‐CT), but more evidence is necessary. </p> </section> <h3 class="title" id="CD009263-sec1-0009">Implications for research</h3> <section id="CD009263-sec1-0009"> <p>In this Cochrane DTA review, only one study reported on the specificity of ¹²³I‐MIBG scintigraphy (<a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>). The other ten studies reported on patients with already proven neuroblastoma. Although the general assumption is that ¹²³I‐MIBG uptake outside the physiological areas proves neuroblastoma, this one study reported 7% false positive findings or 3% if cases with physiological uptake were excluded. It would be helpful to further and better assess the specificity in future studies. </p> <p>Furthermore, it is important to study the possibilities of other additional diagnostic tests in case of negative results of ¹²³I‐MIBG scans in patients suspected of neuroblastoma or already diagnosed with neuroblastoma according to histopathology. One possible additional test is <sup>18</sup>F‐FDG‐PET(‐CT). Only one study concerning <sup>18</sup>F‐FDG imaging was included. Because more and more studies are performed with this diagnostic test for patients with neuroblastoma, we think that with the update of this review more studies on <sup>18</sup>F‐FDG PET(‐CT) can be analysed and more robust conclusions can be drawn. </p> <p>Furthermore, a promising test is the <sup>18</sup>F‐DOPA‐PET‐CT. This test also relies on the metabolism of catecholamines, but has the advantage of better performance due to PET‐technology (<a href="./references#CD009263-bbs2-0272" title="PiccardoA , LopciE , ConteM , FoppianiL , GaraventaA , CabriaA , et al. PET/CT imaging in neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2013;57(1):29‐39. ">Piccardo 2013</a>). Future studies might reveal more details about the diagnostic accuracy of this test. </p> <p>In this Cochrane systematic diagnostic test accuracy review some subgroup analyses were not possible, because studies did not report the data in sufficient detail to assign all patients to subgroups. </p> <p>Only 11 studies were included in this diagnostic test accuracy review. The first reason for the small number of included studies is that we excluded studies that performed ¹³¹I‐MIBG instead of ¹²³I‐MIBG scintigraphy. However, a recent publication (<a href="./references#CD009263-bbs2-0269" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood &amp; Cancer2011;56(7):1041‐5. ">Naranjo 2011</a>) reported no evidence of a statistically significant difference in outcome by type of scan. Therefore, for an update of this review it would be advisable to take these ¹³¹I‐MIBG scans also into account. A second reason for the small number of included studies was that many studies reported on ¹²³I‐MIBG scintigraphy of less than ten patients which was an exclusion criteria for our review, assuming that less than ten patients could not give robust results. However, if reported clearly, studies with less than ten patients might be able to give reliable data and pooling them would be an opportunity for an update of this review. A last reason is that the number of patients with a neuroblastoma per centre is small. In the past, many studies reported patients per centre, resulting in a small number of patients per study. Nowadays, more and more centres collaborate to publish results of their patients together, resulting in more robust data. For an update of this review, we hope that these kind of collaborations will result in many studies with a large number of patients and with robust results, so we can include more patients and do more reliable analyses. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009263-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009263-sec1-0001"></div> <div class="table" id="CD009263-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table 1</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Objective 1.1</b> ¹²³<b>I‐MIBG scintigraphy for diagnosing a neuroblastoma and its metastases at first diagnosis or at recurrence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patients/population:</b> children from 0 to 18 years old with a suspected neuroblastoma of any stage at first diagnosis or at recurrence. </p> <p><b>Setting:</b> tertiary care centres of paediatric oncology. </p> <p><b>Index test:</b> ¹²³I‐MIBG scintigraphy (whole‐body(WB), SPECT or SPECT‐CT). </p> <p><b>Reference test:</b> gold standard is histopathology and or bone marrow biopsies/trephine biopsies, but that was not always performed; so also: histopathology during or after treatment (e.g. tissue obtained during surgery), if urinary metabolites were elevated at diagnosis and additional imaging modalities (e.g. ultrasound, CT scan, MRI scan) suggested a neuroblastoma at diagnosis. </p> <p><b>Studies:</b> primary diagnostic cohort studies (retrospective and prospective), cross‐sectional study. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Second covariate</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Specificity</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (studies) unless otherwise stated</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroblastoma at first diagnosis or at recurrence (all stages)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.67 to 1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68<sup>a</sup> </p> <p>(one study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>608</p> <p>(11 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastases (osteomedullary and soft tissue)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.79 to 1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.33 to 0.89</p> <p>(two studies, 45 patients)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> <p>(3 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 1 and 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.60 to 0.76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> <p>(2 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.00 to 1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> <p>(3 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.80 to 1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> <p>(4 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Osteomedullary metastases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.79 to 0.90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.40 to 0.67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(2 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 4S</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> <p>(1 study)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>As only one study, <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>, reported on diseases other than neuroblastoma, the specificity could be calculated for only this one study. This should be kept in mind. This study is the only one reporting at lesion level instead of patient level.<br/> <sup>b</sup>None of the included studies that distinguished stages of neuroblastoma reported on diseases other than neuroblastoma. Therefore, the specificity could not be calculated for any of these studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009263-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table 2</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Objective 2.1 Diagnostic accuracy of</b><sup>18</sup><b>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patients/population:</b> children from 0 to 18 years old with a neuroblastoma of any stage at first diagnosis or at recurrence. </p> <p><b>Setting:</b> tertiary care centres of paediatric oncology. </p> <p><b>Index test:</b><sup>18</sup>F‐FDG‐PET(‐CT) imaging. </p> <p><b>Reference test:</b> gold standard is histopathology and or bone marrow biopsies/trephine biopsies, but that was not always performed; so also: histopathology during or after treatment (e.g. tissue obtained during surgery), if urinary metabolites were elevated at diagnosis and additional imaging modalities (e.g. ultrasound, CT scan, MRI scan) suggested a neuroblastoma at diagnosis. </p> <p><b>Studies:</b> retrospective cohort study </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Second covariate</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Specificity</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (studies)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroblastoma (all stages) at first diagnosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> <p>(1 study)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 1 and 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> <p>(1 study)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> <p>(1 study)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> <p>(1 study)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Only one study reported on the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma tumour and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old (<a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). As all patients had already proven neuroblastoma, true negative findings did not occur in this study and therefore specificity could not be analysed. The study did not demonstrate false negative findings at diagnosis, which suggests that patients might be selected based on uptake on their scan. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009263-sec1-0002" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009263-sec1-0002"></div> <section id="CD009263-sec2-0001"> <h3 class="title" id="CD009263-sec2-0001">Target condition being diagnosed</h3> <p>Neuroblastoma is an embryonic tumour of childhood that originates in the neural crest. It is the second most common extracranial malignant solid tumour of childhood and the most common solid tumour of infancy (<a href="./references#CD009263-bbs2-0259" title="BrodeurGM . Neuroblastoma: biological insights into a clinical enigma. Nature Reviews Cancer2003;3(3):203‐16. ">Brodeur 2003</a>; <a href="./references#CD009263-bbs2-0260" title="CastleberryRP . Neuroblastoma. European Journal of Cancer1997;33(9):1430‐7. ">Castleberry 1997</a>; <a href="./references#CD009263-bbs2-0270" title="ParkJR , EggertA , CaronH . Neuroblastoma: biology, prognosis, and treatment. Pediatric Clinics of North America2008;55(1):97‐120. ">Park 2008</a>). It accounts for 7% of all childhood cancers and for approximately 15% of cancer deaths in children (<a href="./references#CD009263-bbs2-0260" title="CastleberryRP . Neuroblastoma. European Journal of Cancer1997;33(9):1430‐7. ">Castleberry 1997</a>; <a href="./references#CD009263-bbs2-0265" title="MarisJM , HogartyMD , BagatellR , CohnSL . Neuroblastoma. Lancet2007;369(9579):2106‐20. ">Maris 2007</a>; <a href="./references#CD009263-bbs2-0270" title="ParkJR , EggertA , CaronH . Neuroblastoma: biology, prognosis, and treatment. Pediatric Clinics of North America2008;55(1):97‐120. ">Park 2008</a>; <a href="./references#CD009263-bbs2-0283" title="SpixC , PastoreG , SankilaR , StillerCA , Steliarova‐FoucherE . Neuroblastoma incidence and survival in European children (1978‐1997): report from the Automated Childhood Cancer Information System project. European Journal of Cancer2006;42(13):2081‐91. ">Spix 2006</a>). A neuroblastoma might arise anywhere along the sympathetic nervous system (side chain), but is found most frequently in the abdomen (65%). Half of the neuroblastomas arise from the adrenal glands. Other common sites are the neck, chest and pelvis (<a href="./references#CD009263-bbs2-0265" title="MarisJM , HogartyMD , BagatellR , CohnSL . Neuroblastoma. Lancet2007;369(9579):2106‐20. ">Maris 2007</a>; <a href="./references#CD009263-bbs2-0266" title="MarisJM . Recent advances in neuroblastoma. New England Journal of Medicine2010;362(23):2202‐11. ">Maris 2010</a>; <a href="./references#CD009263-bbs2-0270" title="ParkJR , EggertA , CaronH . Neuroblastoma: biology, prognosis, and treatment. Pediatric Clinics of North America2008;55(1):97‐120. ">Park 2008</a>). They particularly occur in children at a young age, with a median age at diagnosis of 17 months (<a href="./references#CD009263-bbs2-0266" title="MarisJM . Recent advances in neuroblastoma. New England Journal of Medicine2010;362(23):2202‐11. ">Maris 2010</a>). Around 50% of patients present with disseminated disease at the time of diagnosis (<a href="./references#CD009263-bbs2-0265" title="MarisJM , HogartyMD , BagatellR , CohnSL . Neuroblastoma. Lancet2007;369(9579):2106‐20. ">Maris 2007</a>; <a href="./references#CD009263-bbs2-0266" title="MarisJM . Recent advances in neuroblastoma. New England Journal of Medicine2010;362(23):2202‐11. ">Maris 2010</a>). Dissemination occurs through lymphatic and hematogenous routes, with involvement of bone, bone marrow and liver (<a href="./references#CD009263-bbs2-0265" title="MarisJM , HogartyMD , BagatellR , CohnSL . Neuroblastoma. Lancet2007;369(9579):2106‐20. ">Maris 2007</a>; <a href="./references#CD009263-bbs2-0266" title="MarisJM . Recent advances in neuroblastoma. New England Journal of Medicine2010;362(23):2202‐11. ">Maris 2010</a>). </p> <p>Neuroblastoma is staged according to the International Neuroblastoma Staging System (INSS) (<a href="#CD009263-tbl-0003">Table 1</a>) (<a href="./references#CD009263-bbs2-0258" title="BrodeurGM , SeegerRC , BarrettA , BertholdF , CastleberryRP , D'AngioG , et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. Journal of Clinical Oncology1988;6(12):1874‐81. ">Brodeur 1988b</a>; <a href="./references#CD009263-bbs2-0042" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a>). Stage 1 or 2 neuroblastoma is localised, stage 3 neuroblastoma consists of regional disease and stage 4 neuroblastoma is marked by distant metastases. A unique pattern of dissemination, limited to the liver, skin and less than 10% of bone marrow in children younger than one year old is defined as stage 4S, which has a potential for spontaneous regression (<a href="./references#CD009263-bbs2-0258" title="BrodeurGM , SeegerRC , BarrettA , BertholdF , CastleberryRP , D'AngioG , et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. Journal of Clinical Oncology1988;6(12):1874‐81. ">Brodeur 1988b</a>; <a href="./references#CD009263-bbs2-0042" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a>). The INSS system is a postsurgical staging system and therefore the International Neuroblastoma Risk Group (INRG) published a new clinical staging system in 2008: the INRG classification system (<a href="#CD009263-tbl-0004">Table 2</a>) (<a href="./references#CD009263-bbs2-0268" title="MonclairT , BrodeurGM , AmbrosPF , BrisseHJ , CecchettoG , HolmesK , et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of Clinical Oncology2009;27(2):298‐303. ">Monclair 2009</a>). </p> <div class="table" id="CD009263-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">International Neuroblastoma Staging System (INSS)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localised tumour with complete gross excision with or without microscopic residual disease; representative ipsilateral lymph nodes negative for tumour microscopically (nodes attached to and removed with the primary tumour may be positive). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localised tumour with incomplete gross resection; representative ipsilateral non‐adherent lymph nodes negative for tumour microscopically. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2B</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localised tumour with or without complete gross excision with ipsilateral non‐adherent lymph nodes positive for tumour; enlarged contralateral lymph nodes must be negative microscopically. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unresectable unilateral tumour infiltrating across the midline<sup>a</sup> with or without regional lymph node involvement, localised unilateral tumour with contralateral regional lymph node involvement, or midline tumour with bilateral extension by infiltration (unresectable) or by lymph node involvement. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any primary tumour with dissemination to distant lymph nodes, bone, bone marrow, liver, skin or other organs (except as defined for stage 4S). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4S</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localised primary tumour (as defined for stage 1, 2A or 2B) with dissemination limited to skin, liver or &lt; 10% of bone marrow (limited to infants &lt; 1 year of age).<sup>b</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Multifocal primary tumours (e.g. bilateral adrenal primary tumours) should be staged according to the greatest extent of disease, as defined in the table, and followed by a subscript 'M' (e.g. 3M). </p> <p><sup>a</sup>The midline is defined as the vertebral column. Tumours originating on one side and crossing the midline must infiltrate to or beyond the opposite side of the vertebral column.<br/> <sup>b</sup>Marrow involvement in stage 4S should be minimal (i.e. &lt; 10% of total nucleated cells identified as malignant on bone marrow biopsy or marrow aspirate). More extensive marrow involvement would be considered to be stage 4. The metaiodobenzylguanidine scan (if performed) should be negative in the marrow (<a href="./references#CD009263-bbs2-0258" title="BrodeurGM , SeegerRC , BarrettA , BertholdF , CastleberryRP , D'AngioG , et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. Journal of Clinical Oncology1988;6(12):1874‐81. ">Brodeur 1988b</a>; <a href="./references#CD009263-bbs2-0042" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a>). </p> </div> </div> <div class="table" id="CD009263-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">International Neuroblastoma Risk Group Staging System</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localised tumour not involving vital structures as defined by the list of image‐defined risk factors and confined to one body compartment. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Locoregional tumour with presence of one or more image‐defined risk factors.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Distant metastatic disease (except stage MS).</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastatic disease in children younger than 18 months with metastases confined to skin, liver or bone marrow, or a combination. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Patients with multifocal primary tumours should be staged according to the greatest extent of disease as defined in the table (<a href="./references#CD009263-bbs2-0268" title="MonclairT , BrodeurGM , AmbrosPF , BrisseHJ , CecchettoG , HolmesK , et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of Clinical Oncology2009;27(2):298‐303. ">Monclair 2009</a>). </p> </div> </div> <p>The clinical course in patients with a neuroblastoma varies enormously, ranging from spontaneous regression to rapid and fatal tumour progression despite extensive treatment (<a href="./references#CD009263-bbs2-0259" title="BrodeurGM . Neuroblastoma: biological insights into a clinical enigma. Nature Reviews Cancer2003;3(3):203‐16. ">Brodeur 2003</a>; <a href="./references#CD009263-bbs2-0260" title="CastleberryRP . Neuroblastoma. European Journal of Cancer1997;33(9):1430‐7. ">Castleberry 1997</a>; <a href="./references#CD009263-bbs2-0270" title="ParkJR , EggertA , CaronH . Neuroblastoma: biology, prognosis, and treatment. Pediatric Clinics of North America2008;55(1):97‐120. ">Park 2008</a>). Known predictors of poor prognosis are stage, age at diagnosis and chromosomal aberrations, such as MYCN (myc myelocytomatosis viral related oncogene, neuroblastoma derived) amplification and chromosomal loss of 1p36 (<a href="./references#CD009263-bbs2-0256" title="BrodeurGM , SeegerRC , SchwabM , VarmusHE , BishopJM . Amplification of N‐myc in untreated human neuroblastomas correlates with advanced disease stage. Science1984;224(4653):1121‐4. ">Brodeur 1984</a>; <a href="./references#CD009263-bbs2-0257" title="BrodeurGM , FongCT , MoritaM , GriffithR , HayesFA , SeegerRC . Molecular analysis and clinical significance of N‐myc amplification and chromosome 1p monosomy in human neuroblastomas. Progress in Clinical and Biological Research1988;271:3‐15. ">Brodeur 1988a</a>; <a href="./references#CD009263-bbs2-0258" title="BrodeurGM , SeegerRC , BarrettA , BertholdF , CastleberryRP , D'AngioG , et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. Journal of Clinical Oncology1988;6(12):1874‐81. ">Brodeur 1988b</a>; <a href="./references#CD009263-bbs2-0042" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a>; <a href="./references#CD009263-bbs2-0261" title="CohnSL , PearsonAD , LondonWB , MonclairT , AmbrosPF , BrodeurGM , et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. Journal of Clinical Oncology2009;27(2):289‐97. ">Cohn 2009</a>). </p> <p>Children with metastatic disease are quite ill at presentation. As the tumour disseminates to the bone, patients often present with bone pain, limping or both. Metastasis in the orbits can cause periorbital ecchymoses (raccoon eyes), sometimes accompanied by proptosis, caused by metastases in the bony orbit. Another symptom is abdominal distension caused by a large tumour. Paraspinal tumours may cause myelum compression, resulting in neurological symptoms, such as motor weakness, pain and sensory loss, which can be medical emergencies (<a href="./references#CD009263-bbs2-0266" title="MarisJM . Recent advances in neuroblastoma. New England Journal of Medicine2010;362(23):2202‐11. ">Maris 2010</a>; <a href="./references#CD009263-bbs2-0270" title="ParkJR , EggertA , CaronH . Neuroblastoma: biology, prognosis, and treatment. Pediatric Clinics of North America2008;55(1):97‐120. ">Park 2008</a>). </p> <p>The treatment of neuroblastoma patients generally consists of induction chemotherapy, surgery, myeloablative chemotherapy with stem cell rescue, radiotherapy or ¹³¹Iodide‐metaiodobenzylguanidine (¹³¹I‐MIBG) therapy or both (<a href="./references#CD009263-bbs2-0265" title="MarisJM , HogartyMD , BagatellR , CohnSL . Neuroblastoma. Lancet2007;369(9579):2106‐20. ">Maris 2007</a>; <a href="./references#CD009263-bbs2-0266" title="MarisJM . Recent advances in neuroblastoma. New England Journal of Medicine2010;362(23):2202‐11. ">Maris 2010</a>; <a href="./references#CD009263-bbs2-0270" title="ParkJR , EggertA , CaronH . Neuroblastoma: biology, prognosis, and treatment. Pediatric Clinics of North America2008;55(1):97‐120. ">Park 2008</a>; <a href="./references#CD009263-bbs2-0288" title="YalçinB , KremerLC , CaronHN , vanDalenEC . High‐dose chemotherapy and autologous haematopoietic stem cell rescue for children with high‐risk neuroblastoma. Cochrane Database of Systematic Reviews2010, Issue 5. [DOI: 10.1002/14651858.CD006301.pub2] ">Yalçin 2010</a>; <a href="./references#CD009263-bbs2-0289" title="YalçinB , KremerLCM , CaronHN , vanDalenEC . High‐dose chemotherapy and autologous haematopoietic stem cell rescue for children with high‐risk neuroblastoma. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006301.pub3] ">Yalçin 2013</a>). </p> </section> <section id="CD009263-sec2-0002"> <h3 class="title" id="CD009263-sec2-0002">Index test(s)</h3> <p>In this Cochrane review we assessed the diagnostic use of Iodine‐123‐metaiodobenzylguanidine (¹²³I‐MIBG) scintigraphy and fluorine‐18‐fluorodeoxy‐glucose (<sup>18</sup>F‐FDG) positron emission tomography (PET) in the detection of a neuroblastoma and its metastases at first diagnosis or at recurrence. ¹²³I‐MIBG scintigraphy can be performed as a two‐dimensional whole‐body (WB) scan or a three‐dimensional single photon emission computed tomography (SPECT) scan, with or without computed tomography (CT) for localisation of neuroblastoma lesions. </p> <p>MIBG, a compound that is a structural analogue of the neurotransmitter norepinephrine, is actively taken up in neuroendocrine cells via the norepinephrine transporter (NET) and is stored in the neurosecretory granules, resulting in a specific concentration in the tumour in contrast to cells of other tissue (<a href="./references#CD009263-bbs2-0285" title="TaggartD , DuboisS , MatthayKK . Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):403‐18. ">Taggart 2008</a>; <a href="./references#CD009263-bbs2-0286" title="VaidyanathanG . Meta‐iodobenzylguanidine and analogues: chemistry and biology. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):351‐68. ">Vaidyanathan 2008</a>). Once labelled with radioactive iodine (¹²³I or ¹³¹I), MIBG scintigraphy can be used for imaging of tumours of neuroendocrine origin, such as neuroblastoma, paraganglioma and phaeochromocytoma (<a href="./references#CD009263-bbs2-0255" title="BoubakerA , Bischof DelaloyeA . MIBG scintigraphy for the diagnosis and follow‐up of children with neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):388‐402. ">Boubaker 2008</a>; <a href="./references#CD009263-bbs2-0285" title="TaggartD , DuboisS , MatthayKK . Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):403‐18. ">Taggart 2008</a>; <a href="./references#CD009263-bbs2-0286" title="VaidyanathanG . Meta‐iodobenzylguanidine and analogues: chemistry and biology. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):351‐68. ">Vaidyanathan 2008</a>). In the past, both ¹²³I‐MIBG and ¹³¹I‐MIBG were used for diagnostic purposes. However, ¹²³I‐MIBG is considered first choice for imaging because it has a more favourable dosimetry and it was assumed that it provided a better image quality than ¹³¹I‐MIBG (<a href="./references#CD009263-bbs2-0254" title="BombardieriE , AktolunC , BaumRP , Bishof‐DelaloyeA , BuscombeJ , ChatalJF , et al. 131I/123I‐metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging2003;30(12):BP132‐9. ">Bombardieri 2003c</a>; <a href="./references#CD009263-bbs2-0255" title="BoubakerA , Bischof DelaloyeA . MIBG scintigraphy for the diagnosis and follow‐up of children with neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):388‐402. ">Boubaker 2008</a>; <a href="./references#CD009263-bbs2-0285" title="TaggartD , DuboisS , MatthayKK . Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):403‐18. ">Taggart 2008</a>). Consequently, ¹²³I‐MIBG is mainly used for diagnostic purposes in international protocols. </p> <p>¹²³I‐MIBG WB or static scans visualise the primary tumour and its metastases two‐dimensional. SPECT enables three‐dimensional imaging of the primary tumour. However, in practice this imaging modality cannot replace WB imaging, because SPECT often does not fully visualise the whole body, but only a selected part of the body (<a href="./references#CD009263-bbs2-0183" title="RufiniV , FisherGA , ShulkinBL , SissonJC , ShapiroB . Iodine‐123‐MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. Journal of Nuclear Medicine1996;37(9):1464‐8. ">Rufini 1996</a>). MIBG‐SPECT can be combined with CT to determine the exact localisation of the primary tumour and its relation to other organ structures (<a href="./references#CD009263-bbs2-0183" title="RufiniV , FisherGA , ShulkinBL , SissonJC , ShapiroB . Iodine‐123‐MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. Journal of Nuclear Medicine1996;37(9):1464‐8. ">Rufini 1996</a>; <a href="./references#CD009263-bbs2-0285" title="TaggartD , DuboisS , MatthayKK . Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):403‐18. ">Taggart 2008</a>). </p> <p>Physiological distribution of ¹²³I‐MIBG can be found in structures that excrete catecholamines, such as the bladder, urinary tract and gastrointestinal system. MIBG usually accumulates in the liver, myocardium, salivary glands and thyroid, and less frequently in the spleen, lungs, brown adipose tissue and skeletal muscles. It is essential to recognise this normal distribution to avoid false positive interpretation of MIBG scans (<a href="./references#CD009263-bbs2-0254" title="BombardieriE , AktolunC , BaumRP , Bishof‐DelaloyeA , BuscombeJ , ChatalJF , et al. 131I/123I‐metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging2003;30(12):BP132‐9. ">Bombardieri 2003c</a>; <a href="./references#CD009263-bbs2-0255" title="BoubakerA , Bischof DelaloyeA . MIBG scintigraphy for the diagnosis and follow‐up of children with neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):388‐402. ">Boubaker 2008</a>). </p> <p>Many drugs can interfere with the uptake or vesicular storage of ¹²³I‐MIBG (or both) (<a href="#CD009263-tbl-0005">Table 3</a>; <a href="./references#CD009263-bbs2-0254" title="BombardieriE , AktolunC , BaumRP , Bishof‐DelaloyeA , BuscombeJ , ChatalJF , et al. 131I/123I‐metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging2003;30(12):BP132‐9. ">Bombardieri 2003c</a>). Therefore, it is important to stop these medications before the procedure to prevent negative results of ¹²³I‐MIBG scans. In cases of severe hypertension, antihypertensive medication is necessary and cannot be stopped. Consequently, the ¹²³I‐MIBG scan may not be reliable, if the patient is treated with an antihypertensive agent that interferes with ¹²³I‐MIBG. On the other hand, ¹²³I‐MIBG scan test results can be negative because of low expression of the norepinephrine transporter (NET) (<a href="./references#CD009263-bbs2-0255" title="BoubakerA , Bischof DelaloyeA . MIBG scintigraphy for the diagnosis and follow‐up of children with neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):388‐402. ">Boubaker 2008</a>; <a href="./references#CD009263-bbs2-0285" title="TaggartD , DuboisS , MatthayKK . Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):403‐18. ">Taggart 2008</a>). Therefore, it is important to perform an additional test in case of a negative ¹²³I‐MIBG scan. </p> <div class="table" id="CD009263-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Medication interfering with MIBG uptake</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Opioids</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cocaine</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tricyclic antidepressants:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amitriptyline, amoxapine, butriptyline, clomipramine, desipramine, doxepine, dothiepin, imipramine, iprindole, lofepramine, loxapine, maprotiline, mazindol, protriptyline, salbutamol, trimipramine </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sympathicomimetics (components of bronchodilators, decongestants and diet aids):</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amphetamine, dopamine, dobutamine, ephedrine, fenoterol, guanethidine, isoetharine, isoprenaline, isoproterenol, metaramimol, methylephedrine, metoserpidine, methoxamine, noradrenaline, nortriptyline, orciprenaline, oxymethazoline, phenoterol, phenilephrine, phenylpropanolamine, pirbuterol, pseudoephedrine, rimiterol, reproterol, salbutamol, terbutaline, tramazoline, xylometazoline </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antihypertensive/cardiovascular agents:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amiodarone, bretylium, debrisoquin, guanethidine, labetalol, methoserpidine, metoprolol, reserpine </p> <p>Calcium channel blockers: amlodipine, diltiazem, isradipine, lidoflazine, nicardipine, nifedipine, nimodipine, verapamil. </p> <p>ACE inhibitors: captopril, enalapril</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antipsychotics (frequent components of anti‐emetic and anti‐allergic agents):</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenothiazines: chlorpromazine, fluphenazine, loxapine, methotrimeprazine, pericyazine, perphenazine, prochlorperazine, promethazine, thiethylperazine, thioridazine, trifluoperazine </p> <p>Thioxanthenes: flupenthixol, maprotiline, trazodone, zuclopenthixol</p> <p>Butyrophenones: benperidol, droperidol, haloperidol, trifluperidol</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><a href="./references#CD009263-bbs2-0254" title="BombardieriE , AktolunC , BaumRP , Bishof‐DelaloyeA , BuscombeJ , ChatalJF , et al. 131I/123I‐metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging2003;30(12):BP132‐9. ">Bombardieri 2003c</a>; <a href="./references#CD009263-bbs2-0282" title="SolankiKK , BomanjiJ , MoyesJ , MatherSJ , TrainerPJ , BrittonKE . A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta‐iodobenzylguanidine (MIBG). Nuclear Medicine Communications1992;13(7):513‐21. ">Solanki 1992</a> </p> </div> </div> <p>Another imaging modality to diagnose neuroblastoma is PET(‐CT) imaging, which uses the glucose metabolism to visualise the primary tumour and metastases with <sup>18</sup>F‐FDG. In contrast to normal cells, cancer cells avidly take up glucose and metabolise it to lactate even when oxygen is abundantly present. This glucose metabolism in cancer cells enables specific detection by PET with the glucose analogue FDG. Although in contrast to ¹²³I‐MIBG imaging, <sup>18</sup>F‐FDG PET(‐CT) imaging is not specific for neuroblastoma tumours, it may be a useful additional imaging modality for diagnosing neuroblastoma (<a href="./references#CD009263-bbs2-0253" title="BombardieriE , AktolunC , BaumRP , Bishof‐DelaloyeA , BuscombeJ , ChatalJF , et al. FDG‐PET: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging2003;30(12):BP115‐24. ">Bombardieri 2003b</a>; <a href="./references#CD009263-bbs2-0157" title="MurphyJJ , TawfeeqM , ChangB , NadelH . Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms. Journal of Pediatric Surgery2008;43(12):2186‐92. ">Murphy 2008</a>; <a href="./references#CD009263-bbs2-0280" title="ShoreRM . Positron emission tomography/computed tomography (PET/CT) in children. Pediatric Annals2008;37(6):404‐12. ">Shore 2008</a>). This imaging modality might have additional value in patients with (false) negative ¹²³I‐MIBG scans. In this case ¹²³I‐MIBG would be the comparator test. </p> </section> <section id="CD009263-sec2-0003"> <h3 class="title" id="CD009263-sec2-0003">Alternative test(s)</h3> <p>The diagnosis neuroblastoma is being made using several tests. All patients suspected of neuroblastoma have a diagnostic work‐up consisting of: clinical examination, testing of excretion of catecholamines in the urine, imaging of the tumour and its metastases and histopathological investigation of the tumour. </p> <p>Excretion of catecholamines in the urine is a non‐invasive test and it is used as a first screening in patients suspected of having a neuroblastoma. Increased excretion of urinary catecholamines indicates the presence of a neuroblastoma, but this test is not positive in all neuroblastoma patients (<a href="./references#CD009263-bbs2-0284" title="StrengerV , KerblR , DornbuschHJ , LadensteinR , AmbrosPF , AmbrosIM , et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatric Blood and Cancer2007;48(5):504‐9. ">Strenger 2007</a>). </p> <p>Tumour biopsy (histopathology) is the gold standard. It is done not only to confirm the diagnosis, but also to investigate the histology of the neuroblastoma, the differentiation of the tumour and genetic abnormalities, which are all correlated with prognosis and play a role in staging the disease. </p> <p>However, sometimes it is not feasible to perform this test (e.g. if the patient is seriously ill or if such a procedure can be life‐ or organ‐threatening because of tumour localisation). In that case, a combination of tests, MIBG scintigraphy, testing of excretion of catecholamines in the urine and imaging of the tumour, is considered second best. </p> <p>For detecting metastases, histopathology is not the optimal test. It is not feasible to confirm every metastatic lesion histologically, so other tests such as MIBG scintigraphy, MRI or CT, or both MRI and CT are needed. </p> <p>Because MIBG scintigraphy is a functional imaging technique, actual measures of the primary tumour (and metastases) and close relationship with other organs and structures (vessels) cannot be made. </p> <p>Next to ¹²³I‐MIBG scintigraphy, other imaging methods, such as ultrasound, CT‐scan or MRI‐imaging, of the primary tumour are performed to measure the size of the tumour (three‐dimensional) and its relation to other organs and structures in order to estimate risks of surgery. However, these imaging modalities are also not specific for neuroblastoma (<a href="./references#CD009263-bbs2-0103" title="KasteSC , McCarvilleMB . Imaging pediatric abdominal tumors. Seminars in Roentgenology2008;43(1):50‐9. ">Kaste 2008b</a>). </p> <p>As all these tests have their own added value to either the diagnosis or therapy decisions, they are all being used side‐by‐side in patients with a suspected neuroblastoma. </p> </section> <section id="CD009263-sec2-0004"> <h3 class="title" id="CD009263-sec2-0004">Rationale</h3> <p>In clinical practice, ¹²³I‐MIBG and <sup>18</sup>F‐FDG‐PET scintigraphy are performed if a neuroblastoma is strongly suspected and other tests, such as urinary catecholamines, are positive and suggestive for a neuroblastoma. Moreover, ¹²³I‐MIBG scintigraphy is not only important for the diagnosis of neuroblastoma, but also for staging and localisation of skeletal lesions. If these are present, MIBG follow‐up scans are performed to assess response to therapy. In case of a MIBG‐negative neuroblastoma, it is difficult to assess response to therapy, so the patients are being submitted to e.g. <sup>18</sup>F‐FDG‐PET(‐CT) scans and other imaging techniques, for which the diagnostic accuracy is not yet well established. </p> <p>Prognosis, treatment and response to therapy of patients with neuroblastoma are currently based on extension scoring of ¹²³I‐MIBG scans (<a href="./references#CD009263-bbs2-0262" title="DecarolisB , SchneiderC , HeroB , SimonT , VollandR , RoelsF , et al. Iodine‐123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. Journal of Clinical Oncology2013;31(7):944‐51. ">Decarolis 2013</a>; <a href="./references#CD009263-bbs2-0267" title="MatthayKK , ShulkinB , LadensteinR , MichonJ , GiammarileF , LewingtonV , et al. Criteria for evaluation of disease extent by (123)I‐metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. British Journal of Cancer2010;102(9):1319‐26. ">Matthay 2010</a>; <a href="./references#CD009263-bbs2-0269" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood &amp; Cancer2011;56(7):1041‐5. ">Naranjo 2011</a>; <a href="./references#CD009263-bbs2-0290" title="YanikGA , ParisiMT , ShulkinBL , NaranjoA , KreissmanSG , LondonWB , et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. Journal of Nuclear Medicine2013;54(4):541‐8. ">Yanik 2013</a>). Therefore, it is important to have a good overview of the sensitivity and specificity of this diagnostic test. In this Cochrane diagnostic test accuracy (DTA) review we also evaluated the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) as an add‐on test in children with suspected neuroblastoma, as well as the diagnostic accuracy of this test as a single diagnostic test and compared with the diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) scintigraphy. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009263-sec1-0003" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009263-sec1-0003"></div> <p>We reviewed three index test combinations: 1. ¹²³I‐MIBG scintigraphy, 2. <sup>18</sup>F‐FDG‐PET(‐CT), and 3. ¹²³I‐MIBG scintigraphy plus <sup>18</sup>F‐FDG‐PET(‐CT). See <a href="#CD009263-fig-0001">Figure 1</a>: flowchart of index tests. </p> <div class="figure" id="CD009263-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow chart index tests in patients with suspected neuroblastoma." data-id="CD009263-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow chart index tests in patients with suspected neuroblastoma.</p> </div> </div> </div> <section id="CD009263-sec2-0005"> <h3 class="title" id="CD009263-sec2-0005">Primary objective </h3> <p>1.1 To determine the diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) scintigraphy for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old.<br/> 1.2 To determine the diagnostic accuracy of negative ¹²³I‐MIBG scintigraphy in combination with <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. In this case <sup>18</sup>F‐FDG‐PET(‐CT) is an add‐on test. </p> </section> <section id="CD009263-sec2-0006"> <h3 class="title" id="CD009263-sec2-0006">Secondary objectives</h3> <p>2.1 To determine the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old.<br/> 2.2 To compare the diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) scintigraphy and of <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. This was performed within and between (objective 1.1 compared to objective 2.1) included studies. ¹²³I‐MIBG (SPECT‐CT) scintigraphy was the comparator test in this case. </p> </section> <section id="CD009263-sec2-0007"> <h3 class="title" id="CD009263-sec2-0007">Investigation of sources of heterogeneity</h3> <p>When assessing study results, we considered methodological and clinical sources of heterogeneity as well as variation in the criteria used to define a positive test result. Several factors may contribute to heterogeneity in diagnostic performance across studies. We investigated, where possible, the potential influence of differences in the following items: </p> <p>Study population:</p> <p> <ul id="CD009263-lst1-0001"> <li> <p>Newly diagnosed versus recurrent neuroblastoma.</p> </li> <li> <p>Stage of disease (1 to 4 and 4S) as an ordinal variable. We reported stage 1 and 2 combined and stage 3, 4 and 4S separately. </p> </li> </ul> </p> <p>Index test radio labelled MIBG (SPECT‐CT) scintigraphy:</p> <p> <ul id="CD009263-lst1-0002"> <li> <p>Time span between injection and scanning (24 or 48 hours) (acquisition time).</p> </li> <li> <p>WB scan versus SPECT‐CT.</p> </li> <li> <p>Interfering medication (<a href="#CD009263-tbl-0005">Table 3</a>). </p> </li> </ul> </p> <p>Reference standard:</p> <p> <ul id="CD009263-lst1-0003"> <li> <p>Type of test: histopathology (reference test 1) versus bone marrow aspirate or trephine biopsy (reference test 2) versus histopathology in combination with excretion of catecholamines in the urine and additional imaging modalities (reference test 3). </p> </li> </ul> </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009263-sec1-0004" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009263-sec1-0004"></div> <section id="CD009263-sec2-0008"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009263-sec3-0001"> <h4 class="title">Types of studies</h4> <p>We included primary diagnostic studies if they compared the results of ¹²³I‐MIBG (SPECT‐CT) scintigraphy, <sup>18</sup>F‐FDG‐PET(‐CT) imaging, or both, with the tests described as reference standards (as defined below) and if they compared the results of both tests with each other. Studies needed to be of a cross‐sectional design or a case series of proven neuroblastoma. Patient selection could be either retrospective or prospective. We excluded case reports, studies that described fewer than ten patients suspected for neuroblastoma and diagnostic case‐control studies. </p> <p>Studies had to report sufficient data to construct (part of) a two‐by‐two table, i.e. at least the absolute number of true positives and false negatives had to be available from the data reported in the primary studies or obtainable from the study authors to calculate the sensitivity and if possible the specificity. ¹²³I‐MIBG scintigraphy is only performed when there is a high suspicion of a neuroblastoma based on clinical information, excretion of catecholamines in the urine and different imaging methods. Therefore, it is expected that mainly the outcome of MIBG scans in patients with finally proven neuroblastoma will be reported and that thus often only sensitivity can be analysed. </p> </section> <section id="CD009263-sec3-0002"> <h4 class="title">Participants</h4> <p>Children from 0 to 18 years old with suspected neuroblastoma and its metastases of any stage at first diagnosis or at recurrence in a tertiary care centre of paediatric oncology. We excluded studies on animals, studies not performed in children with suspected neuroblastoma, studies performed in children with esthesioneuroblastoma and olfactory neuroblastoma, and studies on the therapeutic use of MIBG. </p> </section> <section id="CD009263-sec3-0003"> <h4 class="title">Index tests</h4> <p> <ul id="CD009263-lst1-0004"> <li> <p>¹²³I‐MIBG scintigraphy (WB, SPECT or SPECT‐CT) of a neuroblastoma and its metastases at first diagnosis or at recurrence. </p> </li> <li> <p><sup>18</sup>F‐FDG‐PET(‐CT) scans of a neuroblastoma and its metastases at first diagnosis or at recurrence. </p> </li> <li> <p>¹²³I‐MIGB scintigraphy plus <sup>18</sup>F‐FDG‐PET(‐CT). </p> </li> </ul> </p> </section> <section id="CD009263-sec3-0004"> <h4 class="title">Comparator tests</h4> <p>When <sup>18</sup>F‐FDG‐PET(‐CT) imaging was the index test: </p> <p> <ul id="CD009263-lst1-0005"> <li> <p>¹²³I‐MIBG scintigraphy (WB, SPECT or SPECT‐CT) of a neuroblastoma and its metastases at first diagnosis or at recurrence. </p> </li> </ul> </p> </section> <section id="CD009263-sec3-0005"> <h4 class="title">Target conditions</h4> <p>Neuroblastoma at first diagnosis or at recurrence.</p> </section> <section id="CD009263-sec3-0006"> <h4 class="title">Reference standards</h4> <p>The optimal combination of reference tests is described below. However, we did not exclude studies that did not use the optimal combination of reference tests. </p> <p>The reference tests for the diagnosis of the primary neuroblastoma tumour were as follows: </p> <p> <ol id="CD009263-lst1-0006"> <li> <p>An unequivocal pathological diagnosis according to the Shimada classification or the International Neuroblastoma Pathology Classification (INPC) (<a href="./references#CD009263-bbs2-0256" title="BrodeurGM , SeegerRC , SchwabM , VarmusHE , BishopJM . Amplification of N‐myc in untreated human neuroblastomas correlates with advanced disease stage. Science1984;224(4653):1121‐4. ">Brodeur 1984</a>; <a href="./references#CD009263-bbs2-0263" title="JoshiVV . Peripheral neuroblastic tumors: pathologic classification based on recommendations of international neuroblastoma pathology committee (Modification of shimada classification). Pediatric and Developmental Pathology2000;3(2):184‐99. ">Joshi 2000</a>; <a href="./references#CD009263-bbs2-0271" title="PeuchmaurM , d'AmoreES , JoshiVV , HataJ , RoaldB , DehnerLP , et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer2003;98(10):2274‐81. ">Peuchmaur 2003</a>; <a href="./references#CD009263-bbs2-0275" title="ShimadaH , ChattenJ , NewtonWAJr , SachsN , HamoudiAB , ChibaT , et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age‐linked classification of neuroblastomas. Journal of the National Cancer Institute1984;73(2):405‐16. ">Shimada 1984</a>; <a href="./references#CD009263-bbs2-0276" title="ShimadaH . Tumors of the neuroblastoma group. Pathology (Philadelphia, Pa.)1993;2(1):43‐59. ">Shimada 1993</a>; <a href="./references#CD009263-bbs2-0277" title="ShimadaH , AmbrosIM , DehnerLP , HataJ , JoshiVV , RoaldB . Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer1999;86(2):349‐63. ">Shimada 1999a</a>; <a href="./references#CD009263-bbs2-0278" title="ShimadaH , AmbrosIM , DehnerLP , HataJ , JoshiVV , RoaldB , et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer1999;86(2):364‐72. ">Shimada 1999b</a>; <a href="./references#CD009263-bbs2-0279" title="ShimadaH . The International Neuroblastoma Pathology Classification. Pathologica2003;95(5):240‐1. ">Shimada 2003</a>). Tumour tissue was examined by use of light or electron microscopy with immunohistochemistry. At least two of the following antigens had to be positive: neuron‐specific enolase (NSE), synaptophysin or chromogranin A (CGA). Tissue had to be preferably obtained by the use of Trucut, core‐needle biopsy. However, if this approach was contra‐indicated, fine‐needle aspiration could be used (<a href="./references#CD009263-bbs2-0042" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a>). </p> </li> <li> <p>A bone marrow aspirate or trephine biopsy containing unequivocal tumour cells. These are immunocytologically positive clumps of cells, containing antibodies against at least two of the following antigens: NSE, synaptophysin or CGA (<a href="./references#CD009263-bbs2-0042" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a>). </p> </li> <li> <p>Histopathology during or after treatment (e.g. tissue obtained during surgery), if excretion of catecholamines in the urine was elevated at diagnosis and additional imaging modalities (e.g. ultrasound, CT scan, MRI scan) suggested a neuroblastoma at diagnosis. </p> </li> </ol> </p> <p>Three different tests were used as possible reference standards. If only one of the three reference standards had a positive result, the diagnosis neuroblastoma could be confirmed. However, to reject the diagnosis neuroblastoma all three had to give a negative result. </p> <p>The reference tests for the diagnosis of neuroblastoma metastases (separately from the primary tumour) were as follows: </p> <p> <ul id="CD009263-lst1-0007"> <li> <p>Bone marrow metastases: To determine bone marrow invasion, at least two different puncture sites were mandatory (although four puncture sites should always be aimed for). Representative smears (five smears from each puncture site) and EDTA/heparin bone marrow (3 to 5 mL from each puncture site) had to be sampled for PCR or immunocytology, or both. Only if no fluid bone marrow in sufficient quality or quantity could be aspirated, trephine biopsies from this puncture site are recommended (<a href="./references#CD009263-bbs2-0252" title="BeiskeK , BurchillSA , CheungIY , HiyamaE , SeegerRC , CohnSL , et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT‐PCR: recommendations by the International Neuroblastoma Risk Group Task Force. British Journal of Cancer2009;100(10):1627‐37. ">Beiske 2009</a>). </p> </li> </ul> <ul id="CD009263-lst1-0008"> <li> <p>Bone metastases: Positive lesions on a <sup>99m</sup>‐Tc skeleton scintigraphy, MRI, CT scan, or a combination of these tests. </p> </li> <li> <p>Lymph node metastases: Histologically proven palpable nodes or ultrasound, MRI or CT scan for non‐palpable nodes, or both. </p> </li> <li> <p>Liver metastases: Ultrasound, MRI, CT scan or a combination of these tests.</p> </li> </ul> </p> <p>Diagnosis of neuroblastoma metastases resulted from at least one positive result of these reference tests. The result for the metastases was assumed negative if all reference tests were negative. </p> <p>There are no inadequate reference standards in the diagnostic process of neuroblastoma. Histopathology is the gold standard, but it is not always possible to perform. Therefore other reference tests, when combined, are also needed in the diagnosis of neuroblastoma. </p> </section> </section> <section id="CD009263-sec2-0009"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009263-sec3-0007"> <h4 class="title">Electronic searches</h4> <p>We searched the databases of MEDLINE/PubMed (from 1945 to 11 September 2012) and EMBASE/Ovid (from 1980 to 11 September 2012). The search strategies for the different electronic databases (using a combination of controlled vocabulary and text words) are presented in <a href="./appendices#CD009263-sec2-0017">Appendix 1</a> and <a href="./appendices#CD009263-sec2-0018">Appendix 2</a>. </p> <p>We did not impose language restrictions.</p> </section> <section id="CD009263-sec3-0008"> <h4 class="title">Searching other resources</h4> <p>We located information about studies not registered in MEDLINE and EMBASE, either published or unpublished, by screening the reference lists of relevant articles and review articles. We also scanned the conference proceedings of the International Society for Paediatric Oncology (SIOP), the American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research (ANR) and the Society of Nuclear Medicine (SNM) from 2006 to 2012. If studies were reported in abstracts or conference proceedings we searched for full publications. We checked for unpublished studies by contacting researchers involved in this area. </p> </section> </section> <section id="CD009263-sec2-0010"> <h3 class="title" id="CD009263-sec2-0010">Data collection and analysis</h3> <section id="CD009263-sec3-0009"> <h4 class="title">Selection of studies</h4> <p>After employing the search strategy described previously, one review author performed the initial screening of identified references, excluding studies on animals, studies not performed in children with suspected neuroblastoma, studies performed in children with esthesioneuroblastoma and olfactory neuroblastoma, studies on the therapeutic use of MIBG, case reports and studies that described fewer than ten patients that were suspected of neuroblastoma. Next, two review authors independently identified studies from the remaining references that seemed to meet the inclusion criteria based on title, abstract, or both and screened these full‐text studies. Only full‐text studies that fulfilled all inclusion criteria for this review were eligible for inclusion. We clearly stated reasons for exclusion of any study considered for the review. </p> <p>Both initial and definite selection needed consensus of both review authors. In case of disagreement, a third‐party arbitrator achieved final resolution. </p> </section> <section id="CD009263-sec3-0010"> <h4 class="title">Data extraction and management</h4> <p>Two review authors performed data extraction independently using standardised forms. Data were extracted either on patient or on lesion level when possible. We extracted data on the following items: </p> <p> <ul id="CD009263-lst1-0009"> <li> <p>Article: author, year of publication, journal.</p> </li> <li> <p>Study population: age, sex, neuroblastoma at first diagnosis or at recurrence, stage, inclusion and exclusion criteria, number of subjects (including number eligible for the study, number enrolled in the study, number subjected to the index test and reference standard, number for whom results were reported in the two‐by‐two‐table, reasons for withdrawal). </p> </li> <li> <p>Index tests: ¹²³I‐MIBG scintigraphy, <sup>18</sup>F‐FDG‐PET(‐CT) imaging, or both. </p> </li> <li> <p>Comparator test: ¹²³I‐MIBG scintigraphy, if <sup>18</sup>F‐FDG‐PET(‐CT) imaging was the index test. </p> </li> <li> <p>Interfering medication in case of ¹²³I‐MIBG scintigraphy (<a href="#CD009263-tbl-0005">Table 3</a>). </p> </li> <li> <p>Reference test: type of test.</p> </li> <li> <p>Study methods: basic design of the study (prospective cohort or historical cohort with data collection based on medical records or case‐control study), time span between index test and reference test, treatment between index test and reference test. </p> </li> <li> <p>Data for the two‐by‐two table: true positive, false positive, true negative and false negative rates or, if not available, relevant parameters (sensitivity, specificity or predictive values) to reconstruct the two‐by‐two table. </p> </li> </ul> </p> <p>To test whether the data extraction form worked well, two review authors piloted this form for two studies (<a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). There was a high concordance between the review authors, so we concluded that the form could be used for all included studies. </p> <p>When data were missing in a published report, we attempted to contact the study authors for the missing information. In cases of disagreement, we re‐examined the abstracts and articles and undertook discussion until we achieved consensus. If this was not possible, we achieved final resolution using a third‐party arbitrator. </p> </section> <section id="CD009263-sec3-0011"> <h4 class="title">Assessment of methodological quality</h4> <p>Two review authors independently assessed the methodological quality of each included study using the QUality Assessment of Diagnostic Accuracy Studies (QUADAS) items (<a href="#CD009263-tbl-0006">Table 4</a>) developed by the NHS Centre for Reviews and Dissemination at the University of York, UK (<a href="./references#CD009263-bbs2-0287" title="WhitingP , RutjesAW , ReitsmaJB , BossuytPM , KleijnenJ . The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Research Methodology2003;3:25. ">Whiting 2003</a>). We scored each item as either 'yes', 'no' or 'unclear'. The QUADAS tool items and our scoring interpretations for each item are presented in <a href="#CD009263-tbl-0006">Table 4</a>. We resolved discrepancies between review authors by consensus. If this was not possible, we sought final resolution using a third‐party arbitrator. We did not calculate a summary score estimating the overall quality of an article since the interpretation of such summary scores is problematic and potentially misleading (<a href="./references#CD009263-bbs2-0264" title="JüniP , WitschiA , BlochR , EggerM . The hazards of scoring the quality of clinical trials for meta‐analysis. JAMA1999;282(11):1061‐83. ">Jüni 1999</a>; <a href="./references#CD009263-bbs2-0287" title="WhitingP , RutjesAW , ReitsmaJB , BossuytPM , KleijnenJ . The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Research Methodology2003;3:25. ">Whiting 2003</a>). We presented results in the text, in a graph and in a table. </p> <div class="table" id="CD009263-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">QUADAS tool items and their interpretation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item and guide to classification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Was the spectrum of patients representative of the patients who will receive the test in practice? Is it a selective sample of patients?</b> </p> <p>Differences in demographic or clinical features between the study population and the source population may lead to selection bias or spectrum variation. In this item we will focus on selection bias: is a selective sample of patients included? The age group and method of patient recruitment will be assessed. Classify as: </p> <p> <ul id="CD009263-lst1-0014"> <li> <p>'yes' if the study describes a cohort of children 0 to 18 years old; if the study describes whether a suspected primary or relapsed neuroblastoma is concerned; if the study describes stage of the disease (1 to 4 and 4S). </p> </li> <li> <p>'no' if the study describes patients older than 18 years old; if the study does not describe stage of the disease (1 to 4 and 4S); if the study recruited a group of healthy controls and a group known to have the target disorder. </p> </li> <li> <p>'unclear' if there is insufficient information on these items.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2. Is the reference standard likely to classify the target condition correctly?</b> </p> <p>Estimates of test performance are based on the assumption that the reference standard will identify neuroblastoma with 100% sensitivity and 100% specificity. Such reference standards are rare. Errors due to an imperfect reference standard may bias the estimation of diagnostic performance. For this review acceptable reference standards are: 1) histopathology of primary tumour; or 2) bone marrow aspirates or trephine biopsies; or 3) histopathology during or after treatment, if urinary metabolites are elevated at diagnosis and additional imaging modalities suggest neuroblastoma at diagnosis (<a href="./references#CD009263-bbs2-0042" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a>). Classify as: </p> <p> <ul id="CD009263-lst1-0015"> <li> <p>'yes' if one of these tests is described as the reference test.</p> </li> <li> <p>'no' if one or more reference standards used do not meet the pre‐stated criteria.</p> </li> <li> <p>'unclear' if there is insufficient information on the reference standard.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. Is the time period between reference standard and index test short enough to be reasonably sure that the target condition did not change between the two tests?</b> </p> <p>Ideally the index test and the reference standard should be performed at the same time. If there is a considerable delay, misclassification due to treatment, spontaneous recovery or progression to a more advanced stage of disease may occur. Classify as: </p> <p> <ul id="CD009263-lst1-0016"> <li> <p>'yes' if the time period between index test and reference standard is two weeks or less and no treatment was given in between. </p> </li> <li> <p>'no' if the time period between index test and reference standard is longer than two weeks or if treatment was given in between. </p> </li> <li> <p>'unclear' if there is insufficient information on the time period between index test and reference standard. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4. Did the whole sample or a random selection of the sample receive verification using a reference standard?</b> </p> <p>Partial verification bias occurs when not all of the study group receive confirmation of the diagnosis by the reference standard. Partial verification bias is very likely if the results of the index test influence the decision to perform the reference standard. Classify as: </p> <p> <ul id="CD009263-lst1-0017"> <li> <p>'yes' if it is clear that all patients or a random selection of patients, that received the index test, went on to the reference standard, even if the reference standard is not the same for all patients. </p> </li> <li> <p>'no' if not all patients, that received the index test, went on to the reference standard or if the selection of patients receiving the reference standard was not random. </p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5. Did patients receive the same reference standard regardless of the index test result?</b> </p> <p>Differential verification bias occurs when some of the index test results are verified by different reference standards. This is not unlikely in this review. Classify as: </p> <p> <ul id="CD009263-lst1-0018"> <li> <p>'yes' if the same reference standard is used to verify the true disease status in ≥ 90% of the patients. </p> </li> <li> <p>'no' if different reference standards are used to verify the true disease status in ≥ 10% of the patients. </p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6. Was the reference standard independent of the index test (i.e. the index test did not form part of the reference standard)?</b> </p> <p>Incorporation bias occurs when the result of the index test is used in establishing the final diagnosis. This will probably increase the amount of agreement between index test result and the outcome of the reference standard, and hence overestimate the various measures of diagnostic accuracy. Score: </p> <p> <ul id="CD009263-lst1-0019"> <li> <p>'yes' if the index test is no part of the reference standard.</p> </li> <li> <p>'no' if the index test is part of the reference standard.</p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7. Were the reference standard results interpreted without knowledge of the results of the index test?</b> </p> <p>Review bias occurs when interpretation of the results of the index test may be influenced by knowledge of the results of the reference standard, and vice versa. This may lead to inflated measures of diagnostic accuracy. Classify as: </p> <p> <ul id="CD009263-lst1-0020"> <li> <p>'yes' if the reference test results were interpreted blind to the results of the index test or blinding is dictated by the test order. </p> </li> <li> <p>'no' if reference test results were interpreted with knowledge of the index test results.</p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8. Were the index test results interpreted without knowledge of the results of the reference standard?</b> </p> <p>Review bias occurs when interpretation of the results of the index test may be influenced by knowledge of the results of the reference standard, and vice versa. This may lead to inflated measures of diagnostic accuracy. Classify as: </p> <p> <ul id="CD009263-lst1-0021"> <li> <p>'yes' if the test index test results are interpreted blind to the results of the reference test or blinding is dictated by the test order. </p> </li> <li> <p>'no' if the index test results were interpreted with knowledge of reference test results.</p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9. Were the same clinical data available when the test results were interpreted as would be available when the test is used in practice?</b> </p> <p>The availability of clinical data during interpretation of test results may affect estimates of test performance. Classify as: </p> <p> <ul id="CD009263-lst1-0022"> <li> <p>'yes' if clinical data, like demographic factors (sex and age); patient history and physical examination (e.g. abdominal extension, bone pains, respiratory distress); additional tests (urine catecholamines, ferritin, lactate dehydrogenase (LDH), other imaging modalities) are available when the test results are interpreted. </p> </li> <li> <p>'no' if clinical data, like demographic factors (sex and age), patient history and physical examination (e.g. abdominal extension, bone pains, respiratory distress); additional tests (urine catecholamines, ferritin, LDH, other imaging modalities) are not available when the test results are interpreted. </p> </li> <li> <p>'unclear' if there is insufficient information on which clinical information was available at the time of assessment. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10. Were uninterpretable/intermediate test results reported?</b> </p> <p>Uninterpretable or intermediate test results are often not reported in diagnostic accuracy studies. These uninterpretable or intermediate results are simply removed from the analysis. This may lead to biased assessment of test characteristics. If uninterpretable or intermediate test results occur randomly and are not related to disease status, bias is unlikely. Whatever the cause of uninterpretable results they should be reported in order to estimate their potential influence on diagnostic performance. Classify as: </p> <p> <ul id="CD009263-lst1-0023"> <li> <p>'yes' if all test results are reported for all patients, including uninterpretable, indeterminate or intermediate results. </p> </li> <li> <p>'no' if not all test results are reported for all patients, including uninterpretable, indeterminate or intermediate results. </p> </li> <li> <p>'unclear' if it is unclear whether all results have been reported.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11. Were withdrawals from the study explained?</b> </p> <p>If patients lost to follow‐up differ systematically from those who remain, for whatever reason, estimates of test performance may be biased. Classify as: </p> <p> <ul id="CD009263-lst1-0024"> <li> <p>'yes' if it is clear what happened to all patients who entered the study (e.g. if a flow diagram is reported). </p> </li> <li> <p>'no' if it is clear that not all patients completed the study (did not receive both index test and reference standard). </p> </li> <li> <p>'unclear' if it is unclear whether all patients who entered the study received both index test and reference standard. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12. Were selection criteria clearly described?</b> </p> <p>This refers to whether studies have provided a clear definition of the criteria used as inclusion (0 to 18 years, primary or relapsed neuroblastoma of any stage) or exclusion criteria (&gt; 18 years, phaeochromocytoma, ganglioneuroma only) for entry into the study. Classify as: </p> <p> <ul id="CD009263-lst1-0025"> <li> <p>'yes' if there is a description of how patients were selected for the study.</p> </li> <li> <p>'no' if study selection criteria are not reported.</p> </li> <li> <p>'unclear' if selection criteria are partially reported and there is not enough information to score this item. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13. Was the execution of the index test described in sufficient detail to permit its replication?</b> </p> <p>If tests are executed in different ways, this would be expected to impact on test performance. Details that should be described are: ¹²³I radioactive labelling, <sup>18</sup>F radioactive labelling, dosage, time between infusion and scanning. Score: </p> <p> <ul id="CD009263-lst1-0026"> <li> <p>'yes' if sufficient details or citations to permit replication of the index test are described or if this is done according to protocol. </p> </li> <li> <p>'no' if sufficient details or citations to permit replication of the index test are not described. </p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14. Was the execution of the reference standard described in sufficient detail to permit its replication?</b> </p> <p>If tests are executed in different ways, this would be expected to impact on test performance. </p> <p>Details that should be described for diagnosing the primary tumour are: pathologic diagnosis by a biopsy OR bone marrow aspirate or trephine biopsy; Shimada or INPCC classification. </p> <p>Details that should be described for diagnosing metastases are: positive bone marrow or trephine aspirates; OR positive lesions on ⁹⁹m‐Tc skeleton scintigraphy, MRI or CT scan, or both; OR histologically proven palpable nodes or positive lesions on ultrasound, MRI or CT scan for non‐palpable nodes, or both; OR positive liver lesions on ultrasound, MRI or CT scan, or both. Score: </p> <p> <ul id="CD009263-lst1-0027"> <li> <p>'yes' if sufficient details or citations to permit replication of the reference standard are described or if this is done according to protocol. </p> </li> <li> <p>'no' if sufficient details or citations to permit replication of the reference standard are not described. </p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15. Did the study provide a clear definition of what was considered to be a 'positive' result of the index test?</b> </p> <p>Classify as:</p> <p> <ul id="CD009263-lst1-0028"> <li> <p>'yes' if the study describes what a positive or a negative result, or both, is.</p> </li> <li> <p>'no' if the study does not describe what a positive or a negative result, or both is. </p> </li> <li> <p>Classify as 'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>16. Were data on inter‐observer variation reported and within acceptable range?</b> </p> <p>There may be considerable interobserver variation in scoring a MIBG scan. This may influence the diagnostic performance of the index test. It is difficult to give minimal cut‐off scores for inter‐observer agreement. A kappa or intra‐class correlation coefficient (ICC) of 0.70 is considered to be acceptable. Classify as: </p> <p> <ul id="CD009263-lst1-0029"> <li> <p>'yes' if information on inter‐observer variation is given, and the results are acceptable.</p> </li> <li> <p>'no' if information on inter‐observer variation is given, and the results demonstrate poor agreement. </p> </li> <li> <p>'unclear' if there is insufficient information on inter‐observer variation.</p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> <p>To test whether the QUADAS form worked well, two review authors piloted this form for three studies (<a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). There was a high concordance between the review authors, so we concluded that the form could be used for all included studies. </p> </section> <section id="CD009263-sec3-0012"> <h4 class="title">Statistical analysis and data synthesis</h4> <p>For the diagnosis of neuroblastoma, we planned to perform a random‐effects meta‐analysis of sensitivity of all included studies. The logit transformed value of sensitivity was to be meta‐analyzed using a random‐effects model to estimate the amount of between‐study variance across studies and the "exact" binomial distribution was to be used to account for the within‐study variance of each study (i.e. the precision by which sensitivity has been measured). We planned to perform these analyses in SAS 9.1 (<a href="./references#CD009263-bbs2-0274" title="SAS Institute Inc.. Statistical Analysis System (SAS) 9.1. Cary, NC, USA: SAS Institute Inc., 2004.. ">SAS 9.1 2004</a>) using the non‐linear mixed effect module (PROC NLMIXED). However, these analyses were not possible because only one study provided data on false positive results. </p> <p>We aimed to extract from each included study the two‐by‐two tables (consisting of at least true positives and false negatives) to calculate the sensitivity and, if possible, the specificity. We generated a paired forest plot showing estimates of sensitivity and specificity. The forest plot provides a visual impression of the precision by which sensitivity and specificity have been measured in each study, as well as an indication of the amount of variability in these parameters across studies. We did not plot pairs of sensitivity and specificity from each study in receiver operating characteristic (ROC), because only one study provided data to calculate specificity for diagnosing neuroblastoma in general and only three studies provided data on both sensitivity and specificity for diagnosing metastases. </p> <p>In the analyses we differentiated between lesions detected in several regions when possible. </p> </section> <section id="CD009263-sec3-0013"> <h4 class="title">Investigations of heterogeneity</h4> <p>First, we investigated heterogeneity through visual inspection of the forest plots. We planned to more formally examine the effects of covariates on sensitivity, specificity, or both in the bivariate model, if sufficient data in the individual studies were available (data in at least four studies for each level of a covariate) to investigate heterogeneity. However, this was not possible. </p> </section> <section id="CD009263-sec3-0014"> <h4 class="title">Sensitivity analyses</h4> <p>To assess whether methodological quality influenced the results we planned to perform sensitivity analyses for the following individual quality items of QUADAS (<a href="#CD009263-tbl-0006">Table 4</a>). However, due to limited information on these items in these studies and a lack of discrimination within these items, it was not possible to do this. </p> <p> <ul id="CD009263-lst1-0010"> <li> <p>Item 1: different stages of the disease and newly diagnosed versus recurrent neuroblastoma may result in different groups. </p> </li> <li> <p>Item 4: partial verification bias.</p> </li> <li> <p>Item 5: differential verification bias.</p> </li> <li> <p>Item 11: withdrawals from the study may differ systematically from those who remain.</p> </li> <li> <p>Item 13: the execution of the index test may differ between clinical centres and may consequently lead to various results, e.g. the index test can be performed with different techniques, time of scanning after infusion (4h, 12h, 24h) or with different equipments. These differences might give different test results. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009263-sec1-0005" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009263-sec1-0005"></div> <section id="CD009263-sec2-0011"> <h3 class="title" id="CD009263-sec2-0011">Results of the search</h3> <p>The electronic database searches yielded a total of 4693 references. We excluded 3204 references after initial screening of titles for the following reasons: studies described fewer than ten patients, were case reports, studies on animals, studies not performed in children with suspected neuroblastoma, studies performed in children with esthesioneuroblastoma and olfactory neuroblastoma or studies on the therapeutic use of MIBG (see <a href="#CD009263-fig-0002">Figure 2</a>). After screening of titles and abstracts of the 1489 remaining references, we identified 246 studies that were assessed in full‐text; we excluded 1243 studies because they did not meet the inclusion criteria (i.e. studies reporting fewer than ten patients, case reports, studies on animals, studies not performed in children with suspected neuroblastoma, studies performed in children with esthesioneuroblastoma and olfactory neuroblastoma, studies on the therapeutic use of MIBG and duplicate studies). Of the 246 full‐text studies, 11 studies fulfilled the inclusion criteria (see the <a href="./references#CD009263-sec2-0021" title="">Characteristics of included studies</a> table). For 24 studies we need additional information to assess whether they could be included and these are awaiting further assessment (see the <a href="./references#CD009263-sec2-0023" title="">Characteristics of studies awaiting classification</a> table). Three studies were not in English and are yet to be translated (see the <a href="./references#CD009263-sec2-0023" title="">Characteristics of studies awaiting classification</a> table). Six studies appeared to be conference proceedings that were not published as full‐text yet and are awaiting further assessment (see the <a href="./references#CD009263-sec2-0023" title="">Characteristics of studies awaiting classification</a> table). We excluded a total of 202 studies after assessing the full‐text study for reasons described in the <a href="./references#CD009263-bbs1-0002" title="">Excluded studies</a> table. </p> <div class="figure" id="CD009263-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Flow diagram: Inclusion process." data-id="CD009263-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram: Inclusion process.</p> </div> </div> </div> <p>Additionally, we identified one conference proceeding after scanning the reference lists of relevant articles and reviews (see the <a href="./references#CD009263-sec2-0023" title="">Characteristics of studies awaiting classification</a> table). Consultation of researchers in the field did not identify any ongoing studies. After scanning the conference proceedings of SIOP, ANR and SNM, we found four additional conference proceedings that have not been published as full‐text yet and are awaiting further assessment (see the <a href="./references#CD009263-sec2-0023" title="">Characteristics of studies awaiting classification</a> table). We did not identify any relevant conference proceedings after scanning the conference proceedings of ASCO. </p> <section id="CD009263-sec3-0015"> <h4 class="title">Included studies</h4> <p>We have summarised the characteristics of the included studies below. For more detailed information see the <a href="http://www.archie.cochrane.org/sections/documents/view?document=60533348873545919391101216111740%26format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES" target="_blank">Characteristics of included studies</a> table. </p> <p>In total, the 11 studies included 844 participants. In this Cochrane DTA review we report only on 621 eligible patients that fulfilled the inclusion criteria for this review. We excluded patients from four studies that included both diagnostic and follow‐up scans (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0008" title="NeuenschwanderS , OllivierL , ToubeauM , Nguyen‐TanT , GongoraG , ZuckerJM . Local evaluation of abdominal neuroblastoma stage III and IV: use of US, CT, and 123 I‐meta‐iodobenzylguanidine (MIBG) scintigraphy. Annales de Radiologie (Paris)1987;30(7):491‐6. ">Neuenschwander 1987</a>; <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>), from one study that included both ¹²³I‐ and ¹³¹I‐MIBG scans (<a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a>), from one study that included two adults (<a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>) and from one study that reported on neuroblastoma patients with and without MIBG scintigraphy (<a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>). </p> <p>Five studies did not report on the median age of eligible patients for this review (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>; <a href="./references#CD009263-bbs2-0008" title="NeuenschwanderS , OllivierL , ToubeauM , Nguyen‐TanT , GongoraG , ZuckerJM . Local evaluation of abdominal neuroblastoma stage III and IV: use of US, CT, and 123 I‐meta‐iodobenzylguanidine (MIBG) scintigraphy. Annales de Radiologie (Paris)1987;30(7):491‐6. ">Neuenschwander 1987</a>; <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). Four studies reported an age range from 0 to 15.2 years (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>; <a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). One study reported a median age of four years (<a href="./references#CD009263-bbs2-0005" title="IvanovaAA , SokolovAV , YalfimovAN , SavchenkoON . Role of 123‐I‐metaiodobenzylguanidine imaging as a component in the diagnosis and treatment of neuroblastoma [Russian]. Voprosy Onkologii2008;54(4):521‐4. ">Ivanova 2008</a>) and one a median of 0.4 years (<a href="./references#CD009263-bbs2-0006" title="Labreveux de CervensC , HartmannO , BonninF , CouanetD , Valteau‐CouanetD , LumbrosoJ , et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?. Medical and Pediatric Oncology1994;22(2):107‐14. ">Labreveux de Cervens 1994</a>). </p> <p>The sex distribution was often not reported for the 621 eligible patients separately from the other patients in the studies. Six studies did not report on the sex distribution of eligible patients for this review (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>; <a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>; <a href="./references#CD009263-bbs2-0008" title="NeuenschwanderS , OllivierL , ToubeauM , Nguyen‐TanT , GongoraG , ZuckerJM . Local evaluation of abdominal neuroblastoma stage III and IV: use of US, CT, and 123 I‐meta‐iodobenzylguanidine (MIBG) scintigraphy. Annales de Radiologie (Paris)1987;30(7):491‐6. ">Neuenschwander 1987</a>; <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>) and five studies did: <a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a> reported 20 boys (61%) and 13 girls (39%); <a href="./references#CD009263-bbs2-0006" title="Labreveux de CervensC , HartmannO , BonninF , CouanetD , Valteau‐CouanetD , LumbrosoJ , et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?. Medical and Pediatric Oncology1994;22(2):107‐14. ">Labreveux de Cervens 1994</a> reported 10 boys (37%) and 17 girls (63%); <a href="./references#CD009263-bbs2-0005" title="IvanovaAA , SokolovAV , YalfimovAN , SavchenkoON . Role of 123‐I‐metaiodobenzylguanidine imaging as a component in the diagnosis and treatment of neuroblastoma [Russian]. Voprosy Onkologii2008;54(4):521‐4. ">Ivanova 2008</a> reported 14 boys (64%) and eight girls (36%); <a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a> reported 124 boys (57%) and 94 girls (43%); and <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a> reported four boys (24%) and 13 girls (76%). </p> <p>The INSS stage distribution was also frequently not reported separately for the 621 eligible patients from the other patients in the studies. Five studies did not report on the INSS stage distribution of patients eligible for this review (<a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>; <a href="./references#CD009263-bbs2-0006" title="Labreveux de CervensC , HartmannO , BonninF , CouanetD , Valteau‐CouanetD , LumbrosoJ , et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?. Medical and Pediatric Oncology1994;22(2):107‐14. ">Labreveux de Cervens 1994</a>; <a href="./references#CD009263-bbs2-0005" title="IvanovaAA , SokolovAV , YalfimovAN , SavchenkoON . Role of 123‐I‐metaiodobenzylguanidine imaging as a component in the diagnosis and treatment of neuroblastoma [Russian]. Voprosy Onkologii2008;54(4):521‐4. ">Ivanova 2008</a>; <a href="./references#CD009263-bbs2-0008" title="NeuenschwanderS , OllivierL , ToubeauM , Nguyen‐TanT , GongoraG , ZuckerJM . Local evaluation of abdominal neuroblastoma stage III and IV: use of US, CT, and 123 I‐meta‐iodobenzylguanidine (MIBG) scintigraphy. Annales de Radiologie (Paris)1987;30(7):491‐6. ">Neuenschwander 1987</a>; <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>). Two studies reported on patients with stage 1, 2, 3 and 4 neuroblastoma (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>); two reported on patients with stage 1, 2, 3, 4 and 4S neuroblastoma (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>; <a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>); one reported on patients with stage 3 and 4 neuroblastoma (<a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>); and one reported on patients with stage 4 neuroblastoma only (<a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a>). Three of these studies (<a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>) reported the exact number per INSS stage: 16 patients with stage 1, five with stage 2, six with stage 3, 239 patients with stage 4 and two patients with stage 4S neuroblastoma. </p> <p>Four studies were retrospective cohort studies (<a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0006" title="Labreveux de CervensC , HartmannO , BonninF , CouanetD , Valteau‐CouanetD , LumbrosoJ , et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?. Medical and Pediatric Oncology1994;22(2):107‐14. ">Labreveux de Cervens 1994</a>; <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>), two were prospective cohort studies (<a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>), one was a retrospective cross‐sectional study (<a href="./references#CD009263-bbs2-0005" title="IvanovaAA , SokolovAV , YalfimovAN , SavchenkoON . Role of 123‐I‐metaiodobenzylguanidine imaging as a component in the diagnosis and treatment of neuroblastoma [Russian]. Voprosy Onkologii2008;54(4):521‐4. ">Ivanova 2008</a>) and of four the type of study was not reported (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>; <a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>; <a href="./references#CD009263-bbs2-0008" title="NeuenschwanderS , OllivierL , ToubeauM , Nguyen‐TanT , GongoraG , ZuckerJM . Local evaluation of abdominal neuroblastoma stage III and IV: use of US, CT, and 123 I‐meta‐iodobenzylguanidine (MIBG) scintigraphy. Annales de Radiologie (Paris)1987;30(7):491‐6. ">Neuenschwander 1987</a>). </p> <p>The diagnosis neuroblastoma was confirmed by histopathology in all 11 studies. In three studies both histopathology and bone marrow biopsies were used for the diagnosis neuroblastoma (<a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>; <a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). In one study 11 patients had bone marrow biopsies and contrast‐enhanced CT or MRI, one patient had histopathology of the primary tumour and contrast‐enhanced CT or MRI, and five patients had histopathology of the primary tumour, bone marrow biopsies and contrast‐enhanced CT or MRI (<a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). To evaluate metastatic disease on ¹²³I‐MIBG scans, bone marrow biopsies were used as gold standard in three studies (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). One study reported on a lesion level and used histologic verification as a reference standard for most lesions (<a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>). However, for stage 4 patients histologic verification of all metastases was impossible. Therefore, another reference standard was used: a minimum of six months was used for verification of lesions on follow‐up control examinations. A lesion was classified as a false‐positive finding if it disappeared without tumour therapy during the observation period. A lesion was classified as a true‐positive finding if it persisted or progressed during follow‐up or if it showed clear regression under specific therapy. </p> <p>¹²³I‐MIBG or <sup>18</sup>F‐FDG‐PET scintigraphy was performed for 608 patients at the time of first diagnosis and for 13 patients at the time of a recurrence. Just one study reported on the 13 patients with a recurrent neuroblastoma (<a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). All studies reported on ¹²³I‐MIBG scintigraphy as an index test; one study also reported on ¹²³I‐MIBG scintigraphy as a comparator test and <sup>18</sup>F‐FDG‐PET scintigraphy as an index test (<a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). </p> <p>The administered activity of ¹²³I‐MIBG varied from 3.7 to 5.18 MBq/kg (<a href="./references#CD009263-bbs2-0006" title="Labreveux de CervensC , HartmannO , BonninF , CouanetD , Valteau‐CouanetD , LumbrosoJ , et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?. Medical and Pediatric Oncology1994;22(2):107‐14. ">Labreveux de Cervens 1994</a>; <a href="./references#CD009263-bbs2-0005" title="IvanovaAA , SokolovAV , YalfimovAN , SavchenkoON . Role of 123‐I‐metaiodobenzylguanidine imaging as a component in the diagnosis and treatment of neuroblastoma [Russian]. Voprosy Onkologii2008;54(4):521‐4. ">Ivanova 2008</a>; <a href="./references#CD009263-bbs2-0008" title="NeuenschwanderS , OllivierL , ToubeauM , Nguyen‐TanT , GongoraG , ZuckerJM . Local evaluation of abdominal neuroblastoma stage III and IV: use of US, CT, and 123 I‐meta‐iodobenzylguanidine (MIBG) scintigraphy. Annales de Radiologie (Paris)1987;30(7):491‐6. ">Neuenschwander 1987</a>; <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>), 185 to 370 MBq/1.73m² body surface (<a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>; <a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>) or was in total 111 to 370 MBq (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). One study did not report on the administered activity of ¹²³I‐MIBG (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>). </p> <p>¹²³I‐MIBG scintigraphy was performed 24 hours after administration of ¹²³I‐MIBG in six studies (<a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0006" title="Labreveux de CervensC , HartmannO , BonninF , CouanetD , Valteau‐CouanetD , LumbrosoJ , et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?. Medical and Pediatric Oncology1994;22(2):107‐14. ">Labreveux de Cervens 1994</a>; <a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a>; <a href="./references#CD009263-bbs2-0008" title="NeuenschwanderS , OllivierL , ToubeauM , Nguyen‐TanT , GongoraG , ZuckerJM . Local evaluation of abdominal neuroblastoma stage III and IV: use of US, CT, and 123 I‐meta‐iodobenzylguanidine (MIBG) scintigraphy. Annales de Radiologie (Paris)1987;30(7):491‐6. ">Neuenschwander 1987</a>; <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). One study reported an acquisition time of 24 or 48 hours (<a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>) and one study of 18 to 24 hours (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>). In three studies the acquisition time was not reported (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>; <a href="./references#CD009263-bbs2-0005" title="IvanovaAA , SokolovAV , YalfimovAN , SavchenkoON . Role of 123‐I‐metaiodobenzylguanidine imaging as a component in the diagnosis and treatment of neuroblastoma [Russian]. Voprosy Onkologii2008;54(4):521‐4. ">Ivanova 2008</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). </p> <p>In 91 patients only a WB ¹²³I‐MIBG scan was performed (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>; <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>), in 27 patients a ¹²³I‐MIBG WB scan with SPECT was performed (<a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>), in 264 patients it was unclear wether a ¹²³I‐MIBG WB scan was performed with or without SPECT (<a href="./references#CD009263-bbs2-0005" title="IvanovaAA , SokolovAV , YalfimovAN , SavchenkoON . Role of 123‐I‐metaiodobenzylguanidine imaging as a component in the diagnosis and treatment of neuroblastoma [Russian]. Voprosy Onkologii2008;54(4):521‐4. ">Ivanova 2008</a>; <a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>) and of 239 patients it was not reported (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>; <a href="./references#CD009263-bbs2-0006" title="Labreveux de CervensC , HartmannO , BonninF , CouanetD , Valteau‐CouanetD , LumbrosoJ , et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?. Medical and Pediatric Oncology1994;22(2):107‐14. ">Labreveux de Cervens 1994</a>; <a href="./references#CD009263-bbs2-0008" title="NeuenschwanderS , OllivierL , ToubeauM , Nguyen‐TanT , GongoraG , ZuckerJM . Local evaluation of abdominal neuroblastoma stage III and IV: use of US, CT, and 123 I‐meta‐iodobenzylguanidine (MIBG) scintigraphy. Annales de Radiologie (Paris)1987;30(7):491‐6. ">Neuenschwander 1987</a>). The one study that reported on <sup>18</sup>F‐FDG‐PET scintigraphy described WB scans (<a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). However, it is known that in studies concerning PET‐scintigraphy the definition of WB may indicate from cranium to toe, but sometimes also from base of skull to knees. This information was not provided by any of the studies. </p> <p>Four studies reported that interpretation of the ¹²³I‐MIBG or <sup>18</sup>F‐FDG PET scans was performed by two or more experienced observers (<a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a>; <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>), two studies reported one observer (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>) and five did not report on observers (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>; <a href="./references#CD009263-bbs2-0006" title="Labreveux de CervensC , HartmannO , BonninF , CouanetD , Valteau‐CouanetD , LumbrosoJ , et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?. Medical and Pediatric Oncology1994;22(2):107‐14. ">Labreveux de Cervens 1994</a>; <a href="./references#CD009263-bbs2-0005" title="IvanovaAA , SokolovAV , YalfimovAN , SavchenkoON . Role of 123‐I‐metaiodobenzylguanidine imaging as a component in the diagnosis and treatment of neuroblastoma [Russian]. Voprosy Onkologii2008;54(4):521‐4. ">Ivanova 2008</a>; <a href="./references#CD009263-bbs2-0008" title="NeuenschwanderS , OllivierL , ToubeauM , Nguyen‐TanT , GongoraG , ZuckerJM . Local evaluation of abdominal neuroblastoma stage III and IV: use of US, CT, and 123 I‐meta‐iodobenzylguanidine (MIBG) scintigraphy. Annales de Radiologie (Paris)1987;30(7):491‐6. ">Neuenschwander 1987</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). </p> <p>None of the included studies reported on treatment between index test and reference standard. </p> </section> <section id="CD009263-sec3-0016"> <h4 class="title">Excluded studies</h4> <p>We excluded 202 studies (see <a href="./references#CD009263-sec2-0022" title="">Characteristics of excluded studies</a> table): 85 studies did not report on original research; 55 studies reported on fewer than ten children with a ¹²³I‐MIBG scan at diagnosis; 19 studies reported on patients that were not suspected of having a neuroblastoma but another tumour; 18 studies were no primary diagnostic investigations; 13 studies reported on ¹³¹I‐MIBG scintigraphy and one on bone scintigraphy, instead of ¹²³I‐MIBG scintigraphy; the selection criteria were unclear in five studies and authors were unable to clarify these; two studies reported on patients older than 18 years; one study did not report on humans; three studies were duplicates. </p> </section> </section> <section id="CD009263-sec2-0012"> <h3 class="title">Methodological quality of included studies</h3> <p>The quality assessment results for the individual studies can be found in the <a href="./references#CD009263-sec2-0021" title="">Characteristics of included studies</a> table. <a href="#CD009263-fig-0003">Figure 3</a> and <a href="#CD009263-fig-0004">Figure 4</a> give an overview of all quality assessment items. </p> <div class="figure" id="CD009263-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD009263-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009263-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD009263-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <p>In summary, in 55% of the included studies the patients were representative for the patients that will be subjected to the index test in practice, in 18% of the studies patients were not representative and it was unclear in 27% of the studies. All studies used an acceptable reference standard. The time between the index and the reference test, the index and the comparator test, the comparator and the reference test was not reported in any of the studies. Although only one study provided data on specificity, partial verification bias was avoided in 64% of the studies. These studies only reported on patients with proven neuroblastoma and they all received the same reference standard. Partial verification bias might have played a role in 9% of the studies and it was unclear in 27%. Differential verification bias was avoided in 46% and might have been present in 27% of the included studies; for 27% of the studies this was unclear. Incorporation bias was avoided in 91% and in 9% it was unclear. </p> <p>It was unclear if the reference test results were blinded in all of the studies. The index test results were blinded in 18% of the studies. Observers were blinded for clinical data in 18%, in 18% of the studies clinical data were available to observers, and in 64% of studies it was unclear whether observers were blinded for clinical data. </p> <p>Uninterpretable results were reported in 18% and in 82% this item was unclear. Withdrawals were reported in 36% of the studies and were not reported in 64%. </p> <p>The selection criteria were provided in 73% of the studies and they were not reported in 27%. </p> <p>In 55% of the studies the index test was described in sufficient detail to replicate the test and in 45% this was not the case. The reference test was described in sufficient detail to replicate the test in just 9% of the studies, 82% of the studies did not report on this item and in 9% this item was unclear. A definition of a positive test result was reported in 46% of the studies, it was not reported in 36% of the studies, and in 18% there was no sufficient information about this item. </p> <p>Inter‐observer variation was not reported in any of the 11 studies.</p> </section> <section id="CD009263-sec2-0013"> <h3 class="title" id="CD009263-sec2-0013">Findings</h3> <p>We were able to analyse the sensitivity and specificity of the diagnosis neuroblastoma for 608 of the 621 eligible patients. The remaining 13 patients were reported in two studies and had false positive or true negative results for neuroblastoma based just on negative bone marrow biopsies, which is not a valid method to detect neuroblastoma, but only to detect metastases (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). Of these 13 patients, 12 had a stage 4 neuroblastoma and could therefore be analysed for diagnostic accuracy of the presence of metastases (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). One of the 13 patients had a stage 3 neuroblastoma and therefore could not be analysed for any of the diagnostic accuracies (<a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). </p> <p>We could not differentiate between lesions detected in several regions, because only one study reported on a lesion level (115 lesions in 22 patients) (<a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>). Because of the limited availability of data and because data at lesion level are important for staging and treatment allocation, we included this study. </p> <p>As all studies only included patients with histologically proven neuroblastoma, results do not apply to daily practice of diagnosing neuroblastoma. </p> <p>The true positive fractions per study are represented in <a href="#CD009263-fig-0005">Figure 5</a> and the true negative fraction of one study, <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>, is represented in <a href="#CD009263-fig-0006">Figure 6</a>. </p> <div class="figure" id="CD009263-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Sensitivity of 123I‐MIBG (SPECT‐CT) scintigraphy for detecting a neuroblastoma tumour and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old (with 95% confidence interval).  Abbreviations: n: number of patients with true positive results of ¹²³I‐MIBG scintigraphy, for Pfluger 2003: number of lesions. N: total number of patients with ¹²³I‐MIBG scintigraphy, for Pfluger 2003: total number of lesions." data-id="CD009263-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sensitivity of 123I‐MIBG (SPECT‐CT) scintigraphy for detecting a neuroblastoma tumour and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old (with 95% confidence interval).<br/> Abbreviations: n: number of patients with true positive results of ¹²³I‐MIBG scintigraphy, for <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>: number of lesions. N: total number of patients with ¹²³I‐MIBG scintigraphy, for <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>: total number of lesions. </p> </div> </div> </div> <div class="figure" id="CD009263-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Specificity of ¹²³I‐MIBG (SPECT‐CT) scintigraphy for detecting a neuroblastoma tumour and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old.  Abbreviations: n: number of lesions with true negative results of ¹²³I‐MIBG scintigraphy. N: total number of lesions with ¹²³I‐MIBG scintigraphy. N.A.: not available (no children without the target condition)" data-id="CD009263-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Specificity of ¹²³I‐MIBG (SPECT‐CT) scintigraphy for detecting a neuroblastoma tumour and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old.<br/> Abbreviations: n: number of lesions with true negative results of ¹²³I‐MIBG scintigraphy. N: total number of lesions with ¹²³I‐MIBG scintigraphy. N.A.: not available (no children without the target condition) </p> </div> </div> </div> <section id="CD009263-sec3-0017"> <h4 class="title">Objective 1.1 Diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) scintigraphy for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old </h4> <p>We analysed data of 608 patients out of 621 eligible patients. The sensitivity of the separate studies varied from 67% to 100% (see <a href="#CD009263-fig-0005">Figure 5</a>). The total false negative rate was 11%. Only one study described patients with both suspected and already proven neuroblastoma (<a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>) and therefore specificity could only be evaluated in this study. It was 68% in 22 patients with 115 lesions (see <a href="#CD009263-fig-0006">Figure 6</a>). The findings of this study were determined for each lesion (on a lesion level), while in all other studies they were determined per patient (on a patient level). </p> <p>In <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>, the false positive findings of the ¹²³I‐MIBG scans at diagnosis (n = 8 lesions) were due to: ganglioneuromas (n = 2), hemangioma of the liver (n = 1), focal nodular hyperplasia of the liver (n = 1), normal liver (n = 1), renal pelvis (n = 1) and physiological activity in a normal adrenal gland, bowel or musculature (n = 2), resulting in a specificity of 68%. </p> <p>The diagnostic accuracy of detecting metastases (osteomedullary and soft tissue) separately from the primary tumour of neuroblastoma was analysed in three studies with all 72 eligible patients (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0006" title="Labreveux de CervensC , HartmannO , BonninF , CouanetD , Valteau‐CouanetD , LumbrosoJ , et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?. Medical and Pediatric Oncology1994;22(2):107‐14. ">Labreveux de Cervens 1994</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). In contrast to the diagnosis of the primary tumour, analyses for the diagnostic accuracy of the metastases did include false positive in two and true negative findings in all three studies and therefore sensitivity and specificity could be calculated for these three and two studies, respectively. The sensitivity of ¹²³I‐MIBG scintigraphy for detecting neuroblastoma metastases in the three studies ranged from 79% to 100%. The specificity could be calculated for two of these studies with 45 patients and ranged from 33% to 89%. Of the 72 patients 72% had true positive metastases on the ¹²³I‐MIBG scan, 7% false negative, 7% false positive and 14% true negative. </p> <p>The detection of metastases was also analysed for osteomedullary, lymph node and liver metastases separately. The detection of osteomedullary metastases was reported in four studies with 105 eligible patients (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>; <a href="./references#CD009263-bbs2-0006" title="Labreveux de CervensC , HartmannO , BonninF , CouanetD , Valteau‐CouanetD , LumbrosoJ , et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?. Medical and Pediatric Oncology1994;22(2):107‐14. ">Labreveux de Cervens 1994</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). The sensitivity of these four studies ranged from 33% to 100% and the specificity from 57% to 100%. The detection of lymph node and liver metastases was reported in one study with 33 eligible patients (<a href="./references#CD009263-bbs2-0003" title="HashimotoT , KoizumiK , NishinaT , AbeK . Clinical usefulness of iodine‐123‐MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Annals of Nuclear Medicine2003;17(8):633‐40. ">Hashimoto 2003</a>). For the detection of liver metastases the sensitivity for 33 patients was 80% and the specificity 93%. For the detection of lymph node metastases this was 23% and 100%, respectively. </p> <section id="CD009263-sec4-0001"> <h5 class="title">Subgroup analyses</h5> <p>For some items subgroup analyses were not possible at all (acquisition time and interfering medication), because insufficient data were given to identify subgroups. </p> <section id="CD009263-sec5-0001"> <h6 class="title">Stages of disease</h6> <p>This item was used to compare the diagnostic accuracy of ¹²³I‐MIBG scintigraphy to diagnose the primary tumour in patients with stage 1‐2 vs. stage 3 vs. stage 4 vs. stage 4S. </p> <p>Two studies reported data on diagnostic accuracy of ¹²³I‐MIBG scintigraphy in all 43 eligible patients with stage 1 or 2 neuroblastoma (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). The sensitivity of these studies ranged from 60% to 76%. </p> <p>Three studies reported data on diagnostic accuracy of ¹²³I‐MIBG scintigraphy in 54 of all 55 eligible patients with stage 3 neuroblastoma (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). The sensitivity of these studies ranged from 0% to 100%. </p> <p>Four studies reported data on diagnostic accuracy of ¹²³I‐MIBG scintigraphy in all 344 eligible patients with stage 4 neuroblastoma (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>; <a href="./references#CD009263-bbs2-0007" title="NaranjoA , ParisiMT , ShulkinBL , LondonWB , MatthayKK , KreissmanSG , et al. Comparison of ¹²³I‐metaiodobenzylguanidine (MIBG) and ¹³¹I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer2011;56(7):1041‐5. ">Naranjo 2011a</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>; <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). The sensitivity of these studies ranged from 80% to 100%. </p> <p>Only one study reported data on diagnostic accuracy of ¹²³I‐MIBG scintigraphy in all 13 eligible patients with stage 4S neuroblastoma (<a href="./references#CD009263-bbs2-0001" title="BiasottiS , GaraventaA , VillavecchiaGP , CabriaM , NantronM , DeBernardiB . False‐negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Medical and Pediatric Oncology2000;35(2):153‐5. ">Biasotti 2000</a>). The sensitivity was 100%. </p> <p>Two studies reported on diagnostic accuracy of ¹²³I‐MIBG scintigraphy for detecting osteomedullary metastases of stage 4 neuroblastoma separately from the other stages (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). For the 37 eligible patients with stage 4 disease described in these two studies, the sensitivity ranged from 79% to 90% and the specificity from 40% to 67%. </p> </section> <section id="CD009263-sec5-0002"> <h6 class="title">Newly diagnosed versus recurrent neuroblastoma</h6> <p>Data on the diagnostic accuracy of ¹²³I‐MIBG scintigraphy for detecting neuroblastoma in children from 0 to 18 years, newly diagnosed versus recurrent, were only available for 13 eligible patients in one study (<a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). Of the four patients with a ¹²³I‐MIBG at first diagnosis, two had true positive and two had false negative findings (sensitivity 50%). Of the nine patients with a ¹²³I‐MIBG at recurrence, eight had true positive and one had false negative findings (sensitivity 89%). </p> </section> <section id="CD009263-sec5-0003"> <h6 class="title">Type of reference standard</h6> <p>Diagnostic accuracy of ¹²³I‐MIBG scintigraphy for detecting neuroblastoma in children from 0 to 18 years old per reference standard (histopathology versus bone marrow biopsies) was only provided in one study (<a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). In six children, histopathology as the reference standard gave three true positive and three true negative results (sensitivity 50%). Bone marrow biopsies in all 17 children gave nine true positive, two false positive, two false negative and four true negative findings (sensitivity of 82% and specificity of 67%). The other studies did not give numbers for separate reference standards, so we could not perform any analyses on this item. </p> </section> <section id="CD009263-sec5-0004"> <h6 class="title">Plane WB versus WB SPECT/CT ¹²³I‐MIBG scintigraphy</h6> <p>The sensitivity of ¹²³I‐MIBG scintigraphy for detecting neuroblastoma in children from 0 to 18 years for patients with WB ¹²³I‐MIBG scintigraphy could be analysed with the data of four studies with 62 of 85 eligible patients (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>; <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>). The sensitivity ranged from 67% to 100%. The specificity was only provided in one study for all 115 lesions of 22 eligible patients and was 68% (<a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>). </p> <p>Only one study, <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>, reported the sensitivity of WB ¹²³I‐MIBG scans with SPECT/CT separately from those without for 11 of 17 eligible patients and was 73%. </p> </section> </section> </section> <section id="CD009263-sec3-0018"> <h4 class="title">Objective 1.2 Diagnostic accuracy of negative ¹²³I‐MIBG scintigraphy in combination with <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old </h4> <p>Only one study reported on the diagnostic accuracy of negative ¹²³I‐MIBG scintigraphy in combination with <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children 0 to 18 years (<a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). Two of the 24 eligible patients with proven neuroblastoma had a negative ¹²³I‐MIBG scan and a positive <sup>18</sup>F‐FDG‐PET(‐CT) scan. </p> </section> <section id="CD009263-sec3-0019"> <h4 class="title">Objective 2.1 Diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old </h4> <p>Only one study reported on the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis in children from 0 to 18 years (<a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). This study described data on <sup>18</sup>F‐FDG‐PET(‐CT) scans of all 24 eligible patients with proven neuroblastoma with a sensitivity of 100%. Because all patients had already proven neuroblastoma, false positive and true negative findings did not occur in this study and therefore specificity could not be analysed. </p> <section id="CD009263-sec4-0002"> <h5 class="title">Subgroup analyses</h5> <p>Pooled analyses were not possible, because only one study reported on this objective. However, data on diagnostic accuracy for subgroups of INSS stage within this study were available. For the other subgroups these data were not provided (newly diagnosed versus recurrent neuroblastoma, plane WB versus WB SPECT/CT ¹²³I‐MIBG scintigraphy, type of reference standard, acquisition time and interfering medication). </p> <section id="CD009263-sec5-0005"> <h6 class="title">Stages of disease</h6> <p>The one study with 24 eligible patients that reported on the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a primary neuroblastoma tumour and its metastases in children from 0 to 18 years old (<a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>), described only true positive findings for five patients with stage 1 or 2 disease, 3 patients with stage 3 disease and 16 patients with stage 4 tumours, so a sensitivity of 100%. </p> </section> </section> </section> <section id="CD009263-sec3-0020"> <h4 class="title">Objective 2.2 Comparison of diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) scintigraphy and of <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old </h4> <p>Only one study reported on the diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) scintigraphy versus <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years (<a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). This study described data on all 24 eligible patients with proven neuroblastoma. The sensitivity of ¹²³I‐MIBG scintigraphy was 92% with two false negative results. The sensitivity of <sup>18</sup>F‐FDG‐PET(‐CT) imaging was 100%. The specificity could not be calculated, because only proven neuroblastoma patients were included. So, <sup>18</sup>F‐FDG‐PET(‐CT) imaging had a better sensitivity than ¹²³I‐MIBG scintigraphy. The two ¹²³I‐MIBG negative neuroblastoma were positive on <sup>18</sup>F‐FDG‐PET(‐CT) imaging. </p> <section id="CD009263-sec4-0003"> <h5 class="title">Subgroup analyses</h5> <p>Pooled analyses were not possible because only one study reported on this objective. However, data on diagnostic accuracy for subgroups of INSS stage within this study were available. For the other subgroups these data were not provided (newly diagnosed versus recurrent neuroblastoma, plane WB versus WB SPECT/CT ¹²³I‐MIBG scintigraphy, type of reference standard, acquisition time and interfering medication). </p> <section id="CD009263-sec5-0006"> <h6 class="title">Stages of disease</h6> <p>The one study with 24 eligible patients that compared the diagnostic accuracy of ¹²³I‐MIBG and <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis in children from 0 to 18 years old (<a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>), described two false negative findings on ¹²³I‐MIBG scintigraphy of five patients with stage 1 or 2 disease, resulting in a sensitivity of 60%. <sup>18</sup>F‐FDG‐PET(‐CT) imaging was positive for all five patients with a sensitivity of 100%. Three patients with stage 3 disease and 16 patients with stage 4 tumour had all true positive findings on the ¹²³I‐MIBG scintigraphy and the <sup>18</sup>F‐FDG‐PET(‐CT) imaging, with sensitivities of 100%. We could not calculate specificity because only proven neuroblastoma was described. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009263-sec1-0006" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009263-sec1-0006"></div> <section id="CD009263-sec2-0014"> <h3 class="title" id="CD009263-sec2-0014">Summary of main results</h3> <p>We assessed three index test combinations in this Cochrane DTA review: 1. ¹²³I‐MIBG scintigraphy, 2. <sup>18</sup>F‐FDG‐PET(‐CT), and 3. ¹²³I‐MIBG scintigraphy plus <sup>18</sup>F‐FDG‐PET(‐CT) (<a href="#CD009263-fig-0001">Figure 1</a>). </p> <section id="CD009263-sec3-0021"> <h4 class="title">Objective 1.1 to determine the diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) scintigraphy:</h4> <p>The sensitivity, determined in 608 of 621 eligible patients included in 11 studies, varied from 67% to 100% (<a href="#CD009263-fig-0005">Figure 5</a>; <a href="./full#CD009263-tbl-0001">summary of findings Table 1</a>). The specificity was 68% in 115 lesions in 22 patients and was described in only one study (<a href="#CD009263-fig-0006">Figure 6</a>). </p> <p>The sensitivity for the detection of stage 1 and 2 neuroblastoma with ¹²³I‐MIBG scintigraphy varied from 60 to 76% (two studies), for stage 3 neuroblastoma from 0% to 100% (three studies), for stage 4 neuroblastoma 80% to 100% (four studies), and for stage 4S neuroblastoma the sensitivity was 100% (one study) (<a href="./full#CD009263-tbl-0001">summary of findings Table 1</a>). The range of the sensitivity of stage 3 tumours was quite broad in comparison to that for all tumours. An explanation might be that of the three studies included in this subgroup analysis, <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a> reported on just one patient with a false negative scan, resulting in a sensitivity of 0%. The sensitivity of 100% for stage 4S tumours might also be explained by the small number of included patients, being 13 patients from only one study with all true positive investigations. </p> <p>Three of the 11 studies (in total 72 patients) described the diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) scintigraphy for detecting metastases (soft tissue and osteomedullary) separately from the primary tumour in patients with all neuroblastoma stages (<a href="./full#CD009263-tbl-0001">summary of findings Table 1</a>). The sensitivity ranged from 79% to 100% (three studies) and the specificity from 33% to 89% (two studies). For lymph node metastases the sensitivity was 23% and the specificity 100%; and for liver metastases this was 80% and 93%. Both types of metastases were reported in one study with 33 patients. Osteomedullary metastases were described in four studies with 105 patients. The sensitivity varied from 33% to 100% and the specificity from 57% to 100%. The sensitivity for osteomedullary metastases in only stage 4 neuroblastoma varied from 79% to 90% and a specificity from 40% to 67% (two studies) (<a href="./full#CD009263-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD009263-sec3-0022"> <h4 class="title">Objective 1.2 to determine the diagnostic accuracy of negative ¹²³I‐MIBG scintigraphy in combination with <sup>18</sup>F‐FDG‐PET(‐CT) imaging (<sup>18</sup>F‐FDG‐PET(‐CT) as an add‐on test): </h4> <p>Only one study reported on this objective. For two of the 24 eligible patients with proven neuroblastoma <sup>18</sup>F‐FDG‐PET(‐CT) imaging had additional value. Two patients with a negative ¹²³I‐MIBG scan had a positive <sup>18</sup>F‐FDG‐PET(‐CT) scan. </p> </section> <section id="CD009263-sec3-0023"> <h4 class="title">Objective 2.1 to determine the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging and Objective 2.2 to compare the diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) scintigraphy and of <sup>18</sup>F‐FDG‐PET(‐CT) imaging within and between included studies </h4> <p>The sensitivity of ¹²³I‐MIBG scintigraphy was 92% and of <sup>18</sup>F‐FDG‐PET(‐CT) imaging 100%. We could not analyse the specificity because all patients had already proven neuroblastoma (<a href="./full#CD009263-tbl-0002">summary of findings Table 2</a>). So, for the 24 eligible patients in this study, <sup>18</sup>F‐FDG‐PET(‐CT) imaging had a better sensitivity than ¹²³I‐MIBG (SPECT‐CT) scintigraphy. </p> </section> </section> <section id="CD009263-sec2-0015"> <h3 class="title" id="CD009263-sec2-0015">Strengths and weaknesses of the review</h3> <section id="CD009263-sec3-0024"> <h4 class="title">Limited amount of available data</h4> <p>Likelihood ratios are the most useful outcome parameters to judge the diagnostic test accuracy of the index tests. In the work‐up of neuroblastoma, urine analysis for excretion of catecholamines (a non‐invasive screening tool), diagnostic imaging and ¹²³ MIBG‐scintigraphy are generally performed, before the diagnosis is confirmed by the gold standard: histopathology. </p> <p>Most studies included in our review were studies that investigated the performance of ¹²³I‐MIBG‐scintigraphy versus other imaging techniques, in a cohort of patients with histologically proven neuroblastoma. However, as is described above, this was not the case at the start of the diagnostic work‐up. The ¹²³MIBG‐scans in these studies were commonly assessed without knowing the results of the histopathology.   </p> <p>Of the 11 included studies, nine reported on case series of proven neuroblastoma. One study was a retrospective cross‐sectional study. The final study was a prospective cross‐sectional study that eventually identified only children with neuroblastoma. </p> <p>Only one of the included studies provided data on false‐positive results at a lesion level, not at a patient level. We believe in fact that this is a study of patients with proven neuroblastoma, in which the performance of the two imaging modalities (¹²³I‐MIBG‐scintigraphy and <sup>18</sup>F‐FDG‐PET‐scintigraphy) was tested for all lesions. </p> <p>False‐positive results of metastatic lesions are possible in patients with proven neuroblastoma. Thus we could not calculate likelihood ratios. It is not expected that future studies will assess specificity. </p> <p>Few data were available to calculate the specificity, as no extensive data on true negative and false positive numbers were reported. To calculate the diagnostic accuracy, we indeed need both data on sensitivity and specificity. At the start of this project, we did not expect to find only very limited data on specificity. Now that we know this, we think that the term "the sensitivity to assess the presence of neuroblastoma" for the objectives would have been more appropriate than "diagnostic accuracy". </p> <p>However, we could collect data on true positive and false negative rates to calculate sensitivity. </p> <p>Only few included studies are of a prospective design, but we feel that all of them are studies assessing the sensitivity of MIBG to detect neuroblastoma. Since there is only limited evidence available we included them in the review. </p> <p>We excluded studies with fewer than ten patients suspected for neuroblastoma. There is neither evidence nor guidelines to decide which cut‐off is justified, but generally systematic reviews published in high‐impact journals use a cut‐off of ten patients. Therefore we decided to use 10 as a cut‐off point. </p> <p>Furthermore, we feared for bias, if small patient numbers were selectively reported out of a larger population. Therefore we also excluded case reports. </p> <p>The inclusion of a small number of patients in the studies of <a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a> and <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a> (19 and 13, respectively) might explain the minor sensitivity in comparison to the other studies. Due to small numbers, one scan more or less scored as false negative, might have a great effect on the sensitivity. For <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a> the minor sensitivity might be explained by the fact that the study results were based on a lesion level and not on a patient level. Just one positive lesion is enough for the diagnosis neuroblastoma and just one positive metastatic site is enough to define stage 4 disease. However, patients were probably included in this study with more than one positive lesion. Therefore, sensitivity may be overestimated. </p> <p>Only one study with 24 eligible patients, <a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>, reported on the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging as a single diagnostic test (objective 2.1) and compared to ¹²³I‐MIBG scintigraphy (objective 2.2). Therefore, it is difficult to draw reliable conclusions from analyses on this study. In this study only two patients with negative ¹²³I‐MIBG scans were reported that were positive on <sup>18</sup>F‐FDG‐PET(‐CT) scans (objective 1.2). <sup>18</sup>F‐FDG‐PET(‐CT) imaging is an upcoming diagnostic imaging method for the detection of neuroblastoma and its metastases. It is already considered as an important additional diagnostic method if ¹²³I‐MIBG scintigraphy is negative (<a href="./references#CD009263-bbs2-0272" title="PiccardoA , LopciE , ConteM , FoppianiL , GaraventaA , CabriaA , et al. PET/CT imaging in neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2013;57(1):29‐39. ">Piccardo 2013</a>). We hope that in an update of this Cochrane DTA review we can include more studies on this objective and provide more reliable information on the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging. </p> <p>For some items subgroup analyses were not possible at all (acquisition time and interfering medication), because insufficient data were given to identify subgroups. </p> <p>In this review, the type of the ¹²³I‐MIBG scans (WB, SPECT‐CT or a combination) varied between the studies and not all studies reported on the distinction between these types of scans. The sensitivity of ¹²³I‐MIBG WB scintigraphy (<a href="./references#CD009263-bbs2-0002" title="GordonI , PetersAM , GutmanA , MoronyS , Dicks‐MireauxC , PritchardJ . Skeletal assessment in neuroblastoma‐‐the pitfalls of iodine‐123‐MIBG scans. Journal of Nuclear Medicine1990;31(2):129‐34. ">Gordon 1990</a>; <a href="./references#CD009263-bbs2-0004" title="HugossonC , NymanR , JorulfH , McDonaldP , RifaiA , KofideA , et al. Imaging of abdominal neuroblastoma in children. Acta Radiologica1999;40(5):534‐42. ">Hugosson 1999</a>; <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>; <a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>), as well as of ¹²³I‐MIBG WB SPECT‐CT scintigraphy (<a href="./references#CD009263-bbs2-0010" title="PiccardoA , LopciE , ConteM , GaraventaA , FoppianiL , AltrinettiV , et al. Comparison of 18F‐dopa PET/CT and 123I‐MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging2012;39(1):57‐71. ">Piccardo 2012</a>), was 73%. So, there was no difference in sensitivity for WB versus WB SPECT‐CT scans. However, only one study described WB SPECT‐CT scans of only 11 of 17 eligible patients. In the literature, the addition of SPECT‐CT might change the diagnostic accuracy of ¹²³I‐MIBG scintigraphy (<a href="./references#CD009263-bbs2-0222" title="GelfandMJ , ElgazzarAH , KrissVM , MastersPR , GolschGJ . Iodine‐123‐MIBG SPECT versus planar imaging in children with neural crest tumors. Journal of Nuclear Medicine1994;35(11):1753‐7. ">Gelfand 1994</a>; <a href="./references#CD009263-bbs2-0180" title="RozovskyK , KoplewitzBZ , KrauszY , Revel‐VilkS , WeintraubM , ChisinR , et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. American Journal of Roentgenology2008;190(4):1085‐90. ">Rozovsky 2008</a>; <a href="./references#CD009263-bbs2-0182" title="RufiniV , GiordanoA , DiGiudaD , PetroneA , DebG , DeSioL , et al. (123I)MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Quarterly Journal of Nuclear Medicine1995;39(4 Suppl 1):25‐8. ">Rufini 1995</a>; <a href="./references#CD009263-bbs2-0183" title="RufiniV , FisherGA , ShulkinBL , SissonJC , ShapiroB . Iodine‐123‐MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. Journal of Nuclear Medicine1996;37(9):1464‐8. ">Rufini 1996</a>). Usually it improves the detection of neuroblastoma lesions and it is easier to differentiate pathological from physiological uptake. Therefore, although the sensitivity of both modalities did not differ in this review, it is still important to make a distinction between studies that used WB scintigraphy only and those that added SPECT‐CT. </p> </section> <section id="CD009263-sec3-0025"> <h4 class="title">Reference standards</h4> <p>Three different tests were used as possible reference standards. If only one of the three reference standards had a positive result, the diagnosis neuroblastoma could be confirmed. However, to reject the diagnosis neuroblastoma all three had to give a negative result. For some of the studies, only bone marrow biopsies, but not histopathology, was reported for some patients. Due to sampling error, a negative result of bone marrow aspirates or trephine biopsies does not exclude a primary neuroblastoma tumour or metastatic disease. If in this case no reliable conclusions could be drawn, we excluded these patients from sensitivity and specificity analyses. </p> <p>One study reported on a lesion level (<a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>). Histologic verification of all lesions in stage 4 patients with metastases is impossible. Therefore, another reference standard was used: a minimum of six months was used for verification of lesions on follow‐up control examinations. A lesion was classified as a false‐positive finding if it disappeared without tumour therapy during the observation period. A lesion was classified as a true positive finding if it persisted or progressed during follow‐up or if it showed clear regression under specific therapy. This might explain the fact that this study found more false positive and false negative results than the other studies. The other studies did not report on a lesion level, but on a patient level. Only one positive lesion is then enough to diagnose a neuroblastoma and only one metastatic lesion is enough to classify the patient as stage 4 or 4S. For the diagnosis of neuroblastoma in general, sensitivity and specificity on a lesion level is less important. </p> </section> <section id="CD009263-sec3-0026"> <h4 class="title">Data extraction and quality assessment</h4> <p>The concordance between the review authors on the data extraction and the QUADAS was high. We disagreed on only 2.7% of the items on the data extraction form and on 3.7% of the QUADAS‐form. So, we conclude that the data extraction and quality assessment were reliable. </p> </section> <section id="CD009263-sec3-0027"> <h4 class="title">Limited possibility to assess the eligibility for this review for a substantial amount of studies </h4> <p>Unfortunately it was not possible to assess the eligibility for inclusion in this review for a substantial amount of studies (n = 38). We tried to contact the study authors to obtain the necessary information and if necessary identify translators, but were unsuccessful. We don't know what the impact of this on the review results are. </p> </section> </section> <section id="CD009263-sec2-0016"> <h3 class="title" id="CD009263-sec2-0016">Applicability of findings to the review question</h3> <p>Although many studies report on ¹²³I‐MIBG scintigraphy, this is the first systematic review on diagnostic test accuracy of ¹²³I‐MIBG scintigraphy. In the literature it is often stated that 90% of neuroblastoma tumours take up MIBG (MIBG‐avid) and that around 10% do not (<a href="./references#CD009263-bbs2-0255" title="BoubakerA , Bischof DelaloyeA . MIBG scintigraphy for the diagnosis and follow‐up of children with neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):388‐402. ">Boubaker 2008</a>). In concordance with the literature, we reported 11% of the 608 patients in the 11 included studies with MIBG‐non‐avid neuroblastoma. The reasons for these MIBG‐non‐avid tumours are not entirely clear. Possible modifications in the uptake mechanism or interfering medication may play a role (<a href="./references#CD009263-bbs2-0255" title="BoubakerA , Bischof DelaloyeA . MIBG scintigraphy for the diagnosis and follow‐up of children with neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging2008;52(4):388‐402. ">Boubaker 2008</a>), but most studies do not report on the reasons of MIBG‐non‐avid neuroblastoma lesions. Also intense radiotracer uptake in normal liver, myocardium, salivary glands and gut may blur the picture and small pathological lesions can be less visible. SPECT‐CT might improve the detection of these lesions, but more research is needed before a definitive conclusion can be made. </p> <p>The analyses in this review showed a false negative rate of around 7% for all types of metastases and for osteomedullary metastases specifically. So, investigation of bone marrow aspirates or trephine biopsies, as described in current protocols (<a href="./references#CD009263-bbs2-0268" title="MonclairT , BrodeurGM , AmbrosPF , BrisseHJ , CecchettoG , HolmesK , et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of Clinical Oncology2009;27(2):298‐303. ">Monclair 2009</a>), are justified in all patients at diagnosis. However, these aspirates and biopsies are taken from the iliac crest, so distant metastases might still be missed. Therefore it is worthwhile to perform an additional test, in case of a negative result of WB ¹²³I‐MIBG scintigraphy. For metastases this is of great importance, because the presence of metastases classifies the patient as stage 4 or 4S and this has severe consequences for the prognosis and treatment. A possible candidate as add‐on test might be <sup>18</sup>F‐FDG‐PET(‐CT) or MRI (<a href="./references#CD009263-bbs2-0057" title="CorbettR , OlliffJ , FairleyN , MoyesJ , HusbandJ , PinkertonR , et al. A prospective comparison between magnetic resonance imaging, meta‐iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma. European Journal of Cancer1991;27(12):1560‐4. ">Corbett 1991b</a>; <a href="./references#CD009263-bbs2-0281" title="SiegelMJ , AcharyyaS , HofferFA , WylyJB , FriedmannAM , SnyderBS , et al. Whole‐body MR imaging for staging of malignant tumors in pediatric patients: results of the American College of Radiology Imaging Network 6660 Trial. Radiology2013;266(2):599‐609. ">Siegel 2013</a>). In this Cochrane DTA review we reviewed the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT). When comparing <sup>18</sup>F‐FDG‐PET(CT) imaging to ¹²³I‐MIBG scintigraphy, the sensitivity of <sup>18</sup>F‐FDG‐PET(CT) was better and it had additional value if ¹²³I‐MIBG scintigraphy was negative (all in one study). So, it is important to study this imaging method as a promising add‐on test. </p> <p>Although the specificity of ¹²³I‐MIBG scintigraphy was analysed in just one study, analyses were performed for 115 lesions in 22 patients (<a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>). The general assumption is that MIBG activity on an ¹²³I‐MIBG scan, that is not explained by physiological uptake, is most likely a neuroblastoma tumour. In contrast, <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a> reported false positive findings. The specificity was 68%, but we believe that not all of these false positive results were justified. Some could be considered as physiological uptake, like normal liver (n = 1), renal pelvis (n = 1) and physiological activity of the normal gland, bowel or musculature (n = 2) and then specificity would be 85%. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009263-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/urn:x-wiley:14651858:media:CD009263:CD009263-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_t/tCD009263-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow chart index tests in patients with suspected neuroblastoma." data-id="CD009263-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow chart index tests in patients with suspected neuroblastoma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009263-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/urn:x-wiley:14651858:media:CD009263:CD009263-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_t/tCD009263-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram: Inclusion process." data-id="CD009263-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Flow diagram: Inclusion process.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009263-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/urn:x-wiley:14651858:media:CD009263:CD009263-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_t/tCD009263-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD009263-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009263-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/urn:x-wiley:14651858:media:CD009263:CD009263-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_t/tCD009263-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD009263-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009263-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/urn:x-wiley:14651858:media:CD009263:CD009263-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_t/tCD009263-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Sensitivity of 123I‐MIBG (SPECT‐CT) scintigraphy for detecting a neuroblastoma tumour and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old (with 95% confidence interval).  Abbreviations: n: number of patients with true positive results of ¹²³I‐MIBG scintigraphy, for Pfluger 2003: number of lesions. N: total number of patients with ¹²³I‐MIBG scintigraphy, for Pfluger 2003: total number of lesions." data-id="CD009263-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Sensitivity of 123I‐MIBG (SPECT‐CT) scintigraphy for detecting a neuroblastoma tumour and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old (with 95% confidence interval).<br/> Abbreviations: n: number of patients with true positive results of ¹²³I‐MIBG scintigraphy, for <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>: number of lesions. N: total number of patients with ¹²³I‐MIBG scintigraphy, for <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>: total number of lesions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009263-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/urn:x-wiley:14651858:media:CD009263:CD009263-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_t/tCD009263-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Specificity of ¹²³I‐MIBG (SPECT‐CT) scintigraphy for detecting a neuroblastoma tumour and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old.  Abbreviations: n: number of lesions with true negative results of ¹²³I‐MIBG scintigraphy. N: total number of lesions with ¹²³I‐MIBG scintigraphy. N.A.: not available (no children without the target condition)" data-id="CD009263-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Specificity of ¹²³I‐MIBG (SPECT‐CT) scintigraphy for detecting a neuroblastoma tumour and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old.<br/> Abbreviations: n: number of lesions with true negative results of ¹²³I‐MIBG scintigraphy. N: total number of lesions with ¹²³I‐MIBG scintigraphy. N.A.: not available (no children without the target condition) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/media/CDSR/CD009263/image_n/nCD009263-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009263-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table 1</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Objective 1.1</b> ¹²³<b>I‐MIBG scintigraphy for diagnosing a neuroblastoma and its metastases at first diagnosis or at recurrence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patients/population:</b> children from 0 to 18 years old with a suspected neuroblastoma of any stage at first diagnosis or at recurrence. </p> <p><b>Setting:</b> tertiary care centres of paediatric oncology. </p> <p><b>Index test:</b> ¹²³I‐MIBG scintigraphy (whole‐body(WB), SPECT or SPECT‐CT). </p> <p><b>Reference test:</b> gold standard is histopathology and or bone marrow biopsies/trephine biopsies, but that was not always performed; so also: histopathology during or after treatment (e.g. tissue obtained during surgery), if urinary metabolites were elevated at diagnosis and additional imaging modalities (e.g. ultrasound, CT scan, MRI scan) suggested a neuroblastoma at diagnosis. </p> <p><b>Studies:</b> primary diagnostic cohort studies (retrospective and prospective), cross‐sectional study. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Second covariate</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Specificity</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (studies) unless otherwise stated</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroblastoma at first diagnosis or at recurrence (all stages)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.67 to 1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68<sup>a</sup> </p> <p>(one study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>608</p> <p>(11 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastases (osteomedullary and soft tissue)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.79 to 1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.33 to 0.89</p> <p>(two studies, 45 patients)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> <p>(3 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 1 and 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.60 to 0.76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> <p>(2 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.00 to 1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> <p>(3 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.80 to 1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> <p>(4 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Osteomedullary metastases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.79 to 0.90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 0.40 to 0.67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(2 studies)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 4S</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> <p>(1 study)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>As only one study, <a href="./references#CD009263-bbs2-0009" title="PflugerT , SchmiedC , PornU , LeinsingerG , VollmarC , DreselS , et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology2003;181(4):1115‐24. ">Pfluger 2003</a>, reported on diseases other than neuroblastoma, the specificity could be calculated for only this one study. This should be kept in mind. This study is the only one reporting at lesion level instead of patient level.<br/> <sup>b</sup>None of the included studies that distinguished stages of neuroblastoma reported on diseases other than neuroblastoma. Therefore, the specificity could not be calculated for any of these studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table 1</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009263-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table 2</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Objective 2.1 Diagnostic accuracy of</b><sup>18</sup><b>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patients/population:</b> children from 0 to 18 years old with a neuroblastoma of any stage at first diagnosis or at recurrence. </p> <p><b>Setting:</b> tertiary care centres of paediatric oncology. </p> <p><b>Index test:</b><sup>18</sup>F‐FDG‐PET(‐CT) imaging. </p> <p><b>Reference test:</b> gold standard is histopathology and or bone marrow biopsies/trephine biopsies, but that was not always performed; so also: histopathology during or after treatment (e.g. tissue obtained during surgery), if urinary metabolites were elevated at diagnosis and additional imaging modalities (e.g. ultrasound, CT scan, MRI scan) suggested a neuroblastoma at diagnosis. </p> <p><b>Studies:</b> retrospective cohort study </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Second covariate</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Specificity</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (studies)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroblastoma (all stages) at first diagnosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> <p>(1 study)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 1 and 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> <p>(1 study)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> <p>(1 study)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> <p>(1 study)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Only one study reported on the diagnostic accuracy of <sup>18</sup>F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma tumour and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old (<a href="./references#CD009263-bbs2-0011" title="SharpSE , ShulkinBL , GelfandMJ , SalisburyS , FurmanWL . 123I‐MIBG scintigraphy and 18F‐FDG PET in neuroblastoma. Journal of Nuclear Medicine2009;50(8):1237‐43. ">Sharp 2009a</a>). As all patients had already proven neuroblastoma, true negative findings did not occur in this study and therefore specificity could not be analysed. The study did not demonstrate false negative findings at diagnosis, which suggests that patients might be selected based on uptake on their scan. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table 2</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009263-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">International Neuroblastoma Staging System (INSS)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localised tumour with complete gross excision with or without microscopic residual disease; representative ipsilateral lymph nodes negative for tumour microscopically (nodes attached to and removed with the primary tumour may be positive). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localised tumour with incomplete gross resection; representative ipsilateral non‐adherent lymph nodes negative for tumour microscopically. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2B</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localised tumour with or without complete gross excision with ipsilateral non‐adherent lymph nodes positive for tumour; enlarged contralateral lymph nodes must be negative microscopically. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unresectable unilateral tumour infiltrating across the midline<sup>a</sup> with or without regional lymph node involvement, localised unilateral tumour with contralateral regional lymph node involvement, or midline tumour with bilateral extension by infiltration (unresectable) or by lymph node involvement. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any primary tumour with dissemination to distant lymph nodes, bone, bone marrow, liver, skin or other organs (except as defined for stage 4S). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4S</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localised primary tumour (as defined for stage 1, 2A or 2B) with dissemination limited to skin, liver or &lt; 10% of bone marrow (limited to infants &lt; 1 year of age).<sup>b</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>Multifocal primary tumours (e.g. bilateral adrenal primary tumours) should be staged according to the greatest extent of disease, as defined in the table, and followed by a subscript 'M' (e.g. 3M). </p> <p><sup>a</sup>The midline is defined as the vertebral column. Tumours originating on one side and crossing the midline must infiltrate to or beyond the opposite side of the vertebral column.<br/> <sup>b</sup>Marrow involvement in stage 4S should be minimal (i.e. &lt; 10% of total nucleated cells identified as malignant on bone marrow biopsy or marrow aspirate). More extensive marrow involvement would be considered to be stage 4. The metaiodobenzylguanidine scan (if performed) should be negative in the marrow (<a href="./references#CD009263-bbs2-0258" title="BrodeurGM , SeegerRC , BarrettA , BertholdF , CastleberryRP , D'AngioG , et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. Journal of Clinical Oncology1988;6(12):1874‐81. ">Brodeur 1988b</a>; <a href="./references#CD009263-bbs2-0042" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">International Neuroblastoma Staging System (INSS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009263-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">International Neuroblastoma Risk Group Staging System</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stage</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Localised tumour not involving vital structures as defined by the list of image‐defined risk factors and confined to one body compartment. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Locoregional tumour with presence of one or more image‐defined risk factors.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Distant metastatic disease (except stage MS).</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastatic disease in children younger than 18 months with metastases confined to skin, liver or bone marrow, or a combination. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>Patients with multifocal primary tumours should be staged according to the greatest extent of disease as defined in the table (<a href="./references#CD009263-bbs2-0268" title="MonclairT , BrodeurGM , AmbrosPF , BrisseHJ , CecchettoG , HolmesK , et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of Clinical Oncology2009;27(2):298‐303. ">Monclair 2009</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">International Neuroblastoma Risk Group Staging System</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009263-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Medication interfering with MIBG uptake</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Opioids</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cocaine</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tricyclic antidepressants:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amitriptyline, amoxapine, butriptyline, clomipramine, desipramine, doxepine, dothiepin, imipramine, iprindole, lofepramine, loxapine, maprotiline, mazindol, protriptyline, salbutamol, trimipramine </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sympathicomimetics (components of bronchodilators, decongestants and diet aids):</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amphetamine, dopamine, dobutamine, ephedrine, fenoterol, guanethidine, isoetharine, isoprenaline, isoproterenol, metaramimol, methylephedrine, metoserpidine, methoxamine, noradrenaline, nortriptyline, orciprenaline, oxymethazoline, phenoterol, phenilephrine, phenylpropanolamine, pirbuterol, pseudoephedrine, rimiterol, reproterol, salbutamol, terbutaline, tramazoline, xylometazoline </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antihypertensive/cardiovascular agents:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amiodarone, bretylium, debrisoquin, guanethidine, labetalol, methoserpidine, metoprolol, reserpine </p> <p>Calcium channel blockers: amlodipine, diltiazem, isradipine, lidoflazine, nicardipine, nifedipine, nimodipine, verapamil. </p> <p>ACE inhibitors: captopril, enalapril</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antipsychotics (frequent components of anti‐emetic and anti‐allergic agents):</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenothiazines: chlorpromazine, fluphenazine, loxapine, methotrimeprazine, pericyazine, perphenazine, prochlorperazine, promethazine, thiethylperazine, thioridazine, trifluoperazine </p> <p>Thioxanthenes: flupenthixol, maprotiline, trazodone, zuclopenthixol</p> <p>Butyrophenones: benperidol, droperidol, haloperidol, trifluperidol</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p><a href="./references#CD009263-bbs2-0254" title="BombardieriE , AktolunC , BaumRP , Bishof‐DelaloyeA , BuscombeJ , ChatalJF , et al. 131I/123I‐metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging2003;30(12):BP132‐9. ">Bombardieri 2003c</a>; <a href="./references#CD009263-bbs2-0282" title="SolankiKK , BomanjiJ , MoyesJ , MatherSJ , TrainerPJ , BrittonKE . A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta‐iodobenzylguanidine (MIBG). Nuclear Medicine Communications1992;13(7):513‐21. ">Solanki 1992</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Medication interfering with MIBG uptake</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009263-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">QUADAS tool items and their interpretation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item and guide to classification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Was the spectrum of patients representative of the patients who will receive the test in practice? Is it a selective sample of patients?</b> </p> <p>Differences in demographic or clinical features between the study population and the source population may lead to selection bias or spectrum variation. In this item we will focus on selection bias: is a selective sample of patients included? The age group and method of patient recruitment will be assessed. Classify as: </p> <p> <ul id="CD009263-lst1-0014"> <li> <p>'yes' if the study describes a cohort of children 0 to 18 years old; if the study describes whether a suspected primary or relapsed neuroblastoma is concerned; if the study describes stage of the disease (1 to 4 and 4S). </p> </li> <li> <p>'no' if the study describes patients older than 18 years old; if the study does not describe stage of the disease (1 to 4 and 4S); if the study recruited a group of healthy controls and a group known to have the target disorder. </p> </li> <li> <p>'unclear' if there is insufficient information on these items.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2. Is the reference standard likely to classify the target condition correctly?</b> </p> <p>Estimates of test performance are based on the assumption that the reference standard will identify neuroblastoma with 100% sensitivity and 100% specificity. Such reference standards are rare. Errors due to an imperfect reference standard may bias the estimation of diagnostic performance. For this review acceptable reference standards are: 1) histopathology of primary tumour; or 2) bone marrow aspirates or trephine biopsies; or 3) histopathology during or after treatment, if urinary metabolites are elevated at diagnosis and additional imaging modalities suggest neuroblastoma at diagnosis (<a href="./references#CD009263-bbs2-0042" title="BrodeurGM , PritchardJ , BertholdF , CarlsenNL , CastelV , CastelberryRP , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology1993;11(8):1466‐77. ">Brodeur 1993</a>). Classify as: </p> <p> <ul id="CD009263-lst1-0015"> <li> <p>'yes' if one of these tests is described as the reference test.</p> </li> <li> <p>'no' if one or more reference standards used do not meet the pre‐stated criteria.</p> </li> <li> <p>'unclear' if there is insufficient information on the reference standard.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. Is the time period between reference standard and index test short enough to be reasonably sure that the target condition did not change between the two tests?</b> </p> <p>Ideally the index test and the reference standard should be performed at the same time. If there is a considerable delay, misclassification due to treatment, spontaneous recovery or progression to a more advanced stage of disease may occur. Classify as: </p> <p> <ul id="CD009263-lst1-0016"> <li> <p>'yes' if the time period between index test and reference standard is two weeks or less and no treatment was given in between. </p> </li> <li> <p>'no' if the time period between index test and reference standard is longer than two weeks or if treatment was given in between. </p> </li> <li> <p>'unclear' if there is insufficient information on the time period between index test and reference standard. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4. Did the whole sample or a random selection of the sample receive verification using a reference standard?</b> </p> <p>Partial verification bias occurs when not all of the study group receive confirmation of the diagnosis by the reference standard. Partial verification bias is very likely if the results of the index test influence the decision to perform the reference standard. Classify as: </p> <p> <ul id="CD009263-lst1-0017"> <li> <p>'yes' if it is clear that all patients or a random selection of patients, that received the index test, went on to the reference standard, even if the reference standard is not the same for all patients. </p> </li> <li> <p>'no' if not all patients, that received the index test, went on to the reference standard or if the selection of patients receiving the reference standard was not random. </p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5. Did patients receive the same reference standard regardless of the index test result?</b> </p> <p>Differential verification bias occurs when some of the index test results are verified by different reference standards. This is not unlikely in this review. Classify as: </p> <p> <ul id="CD009263-lst1-0018"> <li> <p>'yes' if the same reference standard is used to verify the true disease status in ≥ 90% of the patients. </p> </li> <li> <p>'no' if different reference standards are used to verify the true disease status in ≥ 10% of the patients. </p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6. Was the reference standard independent of the index test (i.e. the index test did not form part of the reference standard)?</b> </p> <p>Incorporation bias occurs when the result of the index test is used in establishing the final diagnosis. This will probably increase the amount of agreement between index test result and the outcome of the reference standard, and hence overestimate the various measures of diagnostic accuracy. Score: </p> <p> <ul id="CD009263-lst1-0019"> <li> <p>'yes' if the index test is no part of the reference standard.</p> </li> <li> <p>'no' if the index test is part of the reference standard.</p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7. Were the reference standard results interpreted without knowledge of the results of the index test?</b> </p> <p>Review bias occurs when interpretation of the results of the index test may be influenced by knowledge of the results of the reference standard, and vice versa. This may lead to inflated measures of diagnostic accuracy. Classify as: </p> <p> <ul id="CD009263-lst1-0020"> <li> <p>'yes' if the reference test results were interpreted blind to the results of the index test or blinding is dictated by the test order. </p> </li> <li> <p>'no' if reference test results were interpreted with knowledge of the index test results.</p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8. Were the index test results interpreted without knowledge of the results of the reference standard?</b> </p> <p>Review bias occurs when interpretation of the results of the index test may be influenced by knowledge of the results of the reference standard, and vice versa. This may lead to inflated measures of diagnostic accuracy. Classify as: </p> <p> <ul id="CD009263-lst1-0021"> <li> <p>'yes' if the test index test results are interpreted blind to the results of the reference test or blinding is dictated by the test order. </p> </li> <li> <p>'no' if the index test results were interpreted with knowledge of reference test results.</p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9. Were the same clinical data available when the test results were interpreted as would be available when the test is used in practice?</b> </p> <p>The availability of clinical data during interpretation of test results may affect estimates of test performance. Classify as: </p> <p> <ul id="CD009263-lst1-0022"> <li> <p>'yes' if clinical data, like demographic factors (sex and age); patient history and physical examination (e.g. abdominal extension, bone pains, respiratory distress); additional tests (urine catecholamines, ferritin, lactate dehydrogenase (LDH), other imaging modalities) are available when the test results are interpreted. </p> </li> <li> <p>'no' if clinical data, like demographic factors (sex and age), patient history and physical examination (e.g. abdominal extension, bone pains, respiratory distress); additional tests (urine catecholamines, ferritin, LDH, other imaging modalities) are not available when the test results are interpreted. </p> </li> <li> <p>'unclear' if there is insufficient information on which clinical information was available at the time of assessment. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10. Were uninterpretable/intermediate test results reported?</b> </p> <p>Uninterpretable or intermediate test results are often not reported in diagnostic accuracy studies. These uninterpretable or intermediate results are simply removed from the analysis. This may lead to biased assessment of test characteristics. If uninterpretable or intermediate test results occur randomly and are not related to disease status, bias is unlikely. Whatever the cause of uninterpretable results they should be reported in order to estimate their potential influence on diagnostic performance. Classify as: </p> <p> <ul id="CD009263-lst1-0023"> <li> <p>'yes' if all test results are reported for all patients, including uninterpretable, indeterminate or intermediate results. </p> </li> <li> <p>'no' if not all test results are reported for all patients, including uninterpretable, indeterminate or intermediate results. </p> </li> <li> <p>'unclear' if it is unclear whether all results have been reported.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11. Were withdrawals from the study explained?</b> </p> <p>If patients lost to follow‐up differ systematically from those who remain, for whatever reason, estimates of test performance may be biased. Classify as: </p> <p> <ul id="CD009263-lst1-0024"> <li> <p>'yes' if it is clear what happened to all patients who entered the study (e.g. if a flow diagram is reported). </p> </li> <li> <p>'no' if it is clear that not all patients completed the study (did not receive both index test and reference standard). </p> </li> <li> <p>'unclear' if it is unclear whether all patients who entered the study received both index test and reference standard. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12. Were selection criteria clearly described?</b> </p> <p>This refers to whether studies have provided a clear definition of the criteria used as inclusion (0 to 18 years, primary or relapsed neuroblastoma of any stage) or exclusion criteria (&gt; 18 years, phaeochromocytoma, ganglioneuroma only) for entry into the study. Classify as: </p> <p> <ul id="CD009263-lst1-0025"> <li> <p>'yes' if there is a description of how patients were selected for the study.</p> </li> <li> <p>'no' if study selection criteria are not reported.</p> </li> <li> <p>'unclear' if selection criteria are partially reported and there is not enough information to score this item. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13. Was the execution of the index test described in sufficient detail to permit its replication?</b> </p> <p>If tests are executed in different ways, this would be expected to impact on test performance. Details that should be described are: ¹²³I radioactive labelling, <sup>18</sup>F radioactive labelling, dosage, time between infusion and scanning. Score: </p> <p> <ul id="CD009263-lst1-0026"> <li> <p>'yes' if sufficient details or citations to permit replication of the index test are described or if this is done according to protocol. </p> </li> <li> <p>'no' if sufficient details or citations to permit replication of the index test are not described. </p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14. Was the execution of the reference standard described in sufficient detail to permit its replication?</b> </p> <p>If tests are executed in different ways, this would be expected to impact on test performance. </p> <p>Details that should be described for diagnosing the primary tumour are: pathologic diagnosis by a biopsy OR bone marrow aspirate or trephine biopsy; Shimada or INPCC classification. </p> <p>Details that should be described for diagnosing metastases are: positive bone marrow or trephine aspirates; OR positive lesions on ⁹⁹m‐Tc skeleton scintigraphy, MRI or CT scan, or both; OR histologically proven palpable nodes or positive lesions on ultrasound, MRI or CT scan for non‐palpable nodes, or both; OR positive liver lesions on ultrasound, MRI or CT scan, or both. Score: </p> <p> <ul id="CD009263-lst1-0027"> <li> <p>'yes' if sufficient details or citations to permit replication of the reference standard are described or if this is done according to protocol. </p> </li> <li> <p>'no' if sufficient details or citations to permit replication of the reference standard are not described. </p> </li> <li> <p>'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15. Did the study provide a clear definition of what was considered to be a 'positive' result of the index test?</b> </p> <p>Classify as:</p> <p> <ul id="CD009263-lst1-0028"> <li> <p>'yes' if the study describes what a positive or a negative result, or both, is.</p> </li> <li> <p>'no' if the study does not describe what a positive or a negative result, or both is. </p> </li> <li> <p>Classify as 'unclear' if there is insufficient information on this item.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>16. Were data on inter‐observer variation reported and within acceptable range?</b> </p> <p>There may be considerable interobserver variation in scoring a MIBG scan. This may influence the diagnostic performance of the index test. It is difficult to give minimal cut‐off scores for inter‐observer agreement. A kappa or intra‐class correlation coefficient (ICC) of 0.70 is considered to be acceptable. Classify as: </p> <p> <ul id="CD009263-lst1-0029"> <li> <p>'yes' if information on inter‐observer variation is given, and the results are acceptable.</p> </li> <li> <p>'no' if information on inter‐observer variation is given, and the results demonstrate poor agreement. </p> </li> <li> <p>'unclear' if there is insufficient information on inter‐observer variation.</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">QUADAS tool items and their interpretation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009263.pub2/full#CD009263-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009263.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009263-note-1209">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009263-note-1207">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009263-note-1208">Français</a> </li> <li class="section-language"> <a class="" href="ru#CD009263-note-1206">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009263-note-1205">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009263\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009263\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009263\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009263\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009263\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009263.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009263.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009263.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009263.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009263.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724719600"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009263.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724719604"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009263.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e69afed5f1c00',t:'MTc0MDcyNDcxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 